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INTRODUCTION 
 
A panic attack (PA) is a period of intense fear or discomfort, developing 
abruptly and peaking within 10 minutes, and requiring at least four of the 
following thirteen symptoms: palpitations or accelerated heart rate; sweating, 
trembling or shaking; sensations of shortness of breath or smothering; feeling of 
choking, chest pain or discomfort; nausea or abdominal distress; feeling dizzy, 
unsteady, lightheaded, or faint; derealisation or depersonalisation; fear of losing 
control or going crazy; fear of dying; paresthesias; chills or hot flashes ((DSM-
IV; APA, 1994). Panic attacks are common, occurring in 22.7% of population 
(Kessler et al., 2006). Recurrent PA are the hallmark of panic disorder (PD). 
Panic disorder is a major anxiety disorder characterized by recurrent unexpected 
PA and persisting fear of their recurrence or harmful consequences, and is often 
complicated by agoraphobia (DSM-IV, ICD-10) (WHO, 1992; APA, 1994). 
Epidemiological studies have found a high prevalence (one year prevalence of 
2.8%, lifetime prevalence of 4.7%) and early onset of PD, with female prepon-
derance, and serious impairment associated with all panic syndromes (Kessler et 
al., 2006). 
Cholecystokinin (CCK) is a peptide neurotransmitter that has been im-
plicated in the aetiology of PA and PD (Bradwejn & Koszycki, 1994a; 
Bradwejn & Koszycki, 2001). Panic induction with cholecystokinin-tetrapeptide 
(CCK-4) has been established as a valid experimental model of human PA 
(Bradwein et al., 1991; Eser et al., 2007; Kellner, 2012) used to investigate the 
mechanisms of PA and anxiolytic treatments under controlled conditions. CCK-
4, acting as an agonist of the central subtype of CCK receptors, induces PA in 
patients with PD and, to a lesser extent, in healthy volunteers (HV). CCK-
induced panic symptoms resemble spontaneous PA of PD patients (Bradwejn et 
al., 1991; Abelson & Nesse, 1994) suggesting the suitability of such experi-
mental challenge to clinical investigation of panic phenomena. Despite the 
nearly 20 years of research using the CCK-4 challenge paradigm, the mecha-
nisms underlying the panic induction by CCK-4 are not yet fully understood.  
In the context of the interactions between CCK and other neuronal systems 
relevant to the mechanisms of PA, one of the most intriguing neurotransmitters 
is serotonin (5-hydroxytryptamin, 5-HT). Serotonin, potentially having a 
restraining effect on panic symptoms (Deakin & Graeff, 1991), has been 
suggested to have a crucial role in the neurobiology of PD (Bell & Nutt, 1998; 
Maron & Shlik, 2005) and serotonergic drugs are considered to be the treatment 
of choice for PD (Kasper & Resinger, 2001; Pollack et al., 2003). On the other 
hand, 5-HT agonists, such as meta-chloro-phenylpiperazine (m-CPP) and 
fenfluramine, acutely induce panic and/or anxiety symptoms in PD patients 
(Charney et al., 1987; Targum & Marshall, 1989; Kahn et al., 1991). Several 
studies have focused on the modifying role of 5-HT and its precursor 
tryptophan (TRP) on CCK-4-induced symptoms in patients with PD (Bradwejn 
& Koszycki, 1994b; Shlik et al., 1997; van Megen et al., 1997) and in HV 
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(Koszycki et al., 1996; Depot et al., 1999; Maron et al., 2004c). These studies 
have shown that effective antipanic treatment with a serotonergic drug, 
assumingly increasing availability of synaptic 5-HT, lessens CCK-4-induced 
PA in patients with PD. In HV, the effects of 5-HT and TRP on CCK-4-induced 
symptoms have not been so uniform.  
HV and patients with PD seem to differ both, in their sensitivity to CCK-4 
challenge and in their responsiveness to a serotonergic modulation of CCK-4-
induced panic response. Studies suggest that these dissimilarities may at least 
partly be explained by the differences in the brain 5-HT receptor and transporter 
systems (Maron et al., 2004a; Neumeister et al., 2004; Nash et al., 2008) as 
well as in the genes regulating 5-HT system (Hamilton et al., 1999; Maron et 
al., 2004b; Maron et al., 2005a; Perna et al., 2005).   
Altogether, the accumulated data suggested that the functional states of and 
the interaction patterns between CCK and 5-HT systems are distinct in patients 
with PD as compared to HV warranting further research in this area.  
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REVIEW OF THE LITERATURE 
 
Serotonin – cholecystokinin interplay 
 
Preclinical data 
Experimental preclinical studies provide ample evidence of interactions 
between the 5-HT and CCK systems. For example, it was observed that central 
injections of CCK-4 stimulate the metabolism of 5-HT in the rat brain (Itoh et 
al., 1988). In the guinea pig, intraperitoneal administration of butylocarbonyl 
(BOC)-CCK-4 amplified the rise in extracellular 5-HT normally observed in the 
elevated plus-maze model of anxiety, and produced anxiogenic effects. 
Pretreatment with L 365,260, a CCKB receptor antagonist, opposed both 
effects. When administered alone, L 365,260 showed anxiolytic properties, 
decreased basal 5-HT levels, and prevented the rise in 5-HT induced by 
exposure to the elevated plus-maze test (Rex et al., 1994).  
On the other hand, increasing brain 5-HT was shown to lead to an increased 
release of brain CCK (Raiteri et al., 1993; Rosen et al., 1995). These data are 
supported by preclinical data on SSRI administration, showing initial increases 
in CCK transmission and the number of CCK receptors (Rosen et al., 1995; 
Koks et al., 1999). These effects however, normalize upon chronic treatment as 
demonstrated by Harro and colleagues (Harro et al., 1997), who found no 
changes in the density of CCK receptors or in the content of CCK-related 
peptides after long-term treatment with various antidepressants, including 5-HT 
reuptake inhibitors.  
The modulation of endogenous 5-HT3 receptor (5-HT3R) activity also has 
been shown to influence the CCK system. Animal studies have demonstrated 
that 5-HT and 1-phenylbiguanide, a 5-HT3R agonist, enhanced the 
depolarisation-evoked release of CCK from synaptosomes of the rat cerebral 
cortex and the nucleus accumbens. This effect was not observed under basal 
conditions or after pretreatment with 5-HT3R antagonists such as MDL 72222, 
ICS 205–930, and ondansetron. In contrast, the 5-HT1/5-HT2 receptor blockade 
by methiothepin did not antagonize CCK release by 5-HT, indicating that the 
effect is most likely mediated by 5-HT3 receptors located on CCK-releasing 
nerve terminals (Paudice & Raiteri, 1991; Raiteri et al., 1993). The importance 
of 5-HT3 receptors in the regulation of anxiety was further confirmed by Vasar 
and colleagues (Vasar et al., 1993) who showed that intraperitoneal pretreat-
ment of rats with ondansetron completely reversed the antiexploratory effect of 
subcutaneously injected caerulein, a nonselective agonist of CCKA/CCKB 
receptors.  
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Clinical data  
Manipulation of synaptic 5-HT level 
Two approaches for manipulating synaptic 5-HT level have been used in human 
studies. One is the acute tryptophan depletion (TD), which causes a substantial 
transient decrease in the brain 5-HT levels (Young et al., 1985; Bell et al., 
2001). The opposite effect could be achieved with the use of 5-HT precursor 5-
hydroxytryptophan (5-HTP) or a drug acting to increase the brain concentra-
tions of 5-HT (den Boer & Westenberg, 1990; van Vliet et al., 1996). Both 
methods are evidently more informative under conditions of experimental 
challenge with panicogenic agents, such as inhaled carbon dioxide (CO2) or 
CCK-4.  
Previous studies have demonstrated that while TD by itself is not pani-
cogenic in unmedicated PD patients (Goddard et al., 1994), it increased 
ventilation in PD patients (Kent et al., 1996) and revealed susceptibility to PA 
when combined with challenge agents, such as the alpha-2-adrenergic anta-
gonist yohimbine (Goddard et al., 1995) or inhaled CO2 (Miller et al., 2000; 
Schruers et al., 2000). Furthermore, TD reversed the antipanic effect of treat-
ment with an SSRI, paroxetine in PD patients when challenged with flumazenil, 
a benzodiazepine receptor antagonist (Bell et al., 2002). Conversely, the 
administration of 5-HTP inhibited the panic symptoms induced by CO2 
inhalation in patients with PD (Schruers et al., 2002). There is also an earlier 
observation that PD patients felt relief from the effect of 5-HTP (den Boer & 
Westenberg, 1990), and as noted earlier, 5-HT-ergic drugs possess antipanic 
efficacy presumably due to increasing the level of synaptic 5-HT (Kasper & 
Resinger, 2001; Pollack et al., 2003). These findings suggest that a decrease in 
5-HT neurotransmission predisposes to PA, and that the antipanic effect of 
SSRIs depends upon the availability of 5-HT in the brain.  
The respective findings in HV have been less robust than in patients with 
PD. For instance, (Schruers et al., 2002) did not find any significant influence 
of acute administration of 5-HTP on CO2-induced panic in HV, although they 
found significant reduction in panic response by 5-HTP in patients with PD. 
Similarly, the augmenting effects of TD on CO2-induced panic have been more 
pronounced in patients with PD than in HV (Klaassen et al., 1998; Schruers et 
al., 2000).  
Several studies have focused on the modifying role of 5-HT and TRP on 
CCK-4-induced symptoms in patients with PD (Bradwejn & Koszycki, 1994b; 
Shlik et al., 1997; van Megen et al., 1997) and in HV (Koszycki et al., 1996; 
Depot et al., 1999; Maron et al., 2004c). Initially it was shown that effective 
antipanic treatment with nonselective monoamine reuptake inhibitor imipramine 
(Bradwejn & Koszycki, 1994b) or a SSRI (Shlik et al., 1997; van Megen et al., 
1997) lessens CCK-4-induced PA in PD patients. It has been assumed that these 
treatments, in accordance with the theory of Deakin and Graeff (1991), lessen 
CCK-4-induced PA by increasing availability of synaptic 5-HT. In HV, the 
modulating effect of 5-HT or TRP on CCK-4-induced symptoms does not 
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appear so uniform. Koszycki and colleagues (1996) demonstrated that TD 
augmented CCK-4-induced release of adrenocorticotropic hormone (ACTH), 
cortisol and prolactin in healthy males, without influencing the panicogenic 
effect of CCK-4, suggesting that 5-HT system has a role in neuroendocrine, but 
not psychological effects of CCK-4. Maron and colleagues (Maron et al., 
2004c) demonstrated that acute administration of 5-HTP significantly lowered 
the panic rate and intensity of cognitive panic symptoms in female HV, and 
intensity of somatic symptoms in healthy males, indicating gender differences 
in the 5-HT-ergic influence on CCK-4-induced panic. However, no whole 
group antipanic effect was found in this study. Recently Kellner and colleagues 
(2009) found that escitalopram (ESC) had no inhibitory effect on panic 
symptoms elicited by CCK-4 in healthy men.   
Apart from the studies modulating CCK-4-induced PA by increasing or 
decreasing synaptic availability of 5-HT, a few studies undertook to manipulate 
specific 5-HT receptors, in particular the 5-HT3 receptor. After acute 
administration, ondansetron, the antagonist of 5-HT3 receptor, attenuated CCK-
4-induced PA in HV (Depot et al., 1999), but did not prevent the panicogenic 
effects of CCK-4 analogue pentagastrin in patients with PD (McCann et al., 
1997), demonstrating a difference in modulatory potential of this 5-HT3 
receptor antagonist on CCK induced panic between the HV and PD patients. In 
the same study (Depot et al., 1999) it was found that, although after acute 
administration ondansetron attenuated CCK-4-induced PA in HV significantly 
more than placebo, after chronic administration (28 days), while ondansetron 
and placebo groups differed by some hormonal parameters, they did not 
significantly differ in any of the assessed behavioral or cardiovascular para-
meters.  
Thus, the interaction patterns between 5-HT and CCK neuronal systems as 
well as antipanic potential of 5-HT-ergic agents seem to be different in HV vs. 
PD patients, in males vs. females as well as in case of acute vs. chronic 
administration.  
 
Brain imaging of 5-HT receptor  
The brain imaging studies in PD have so far shown both structural and 
functional abnormalities in several brain regions (Graeff & Del-Ben, 2008). 
Additionally, neurochemical alterations have been found in neuroimaging 
studies of gamma-aminobutyric acid (GABA) (Kuikka et al., 1995; Malizia et 
al., 1998; Hasler et al., 2008), 5-HT (Maron et al., 2004a; Neumeister et al., 
2004; Nash et al., 2008), neurokinin (Fujimura et al., 2009) and dopamine 
(Maron et al., 2010b) systems. Different 5-HTT and 5-HT1A (both assumingly 
crucial in 5-HT turnover) receptor binding properties in several brain regions 
have been visualized in multiple brain imaging studies suggesting both state and 
trait dependent differences in 5-HT-ergic system of PD patients and HV as well 
as a possibility of different treatment response to a 5-HT-ergic agent. In a study 
using single photon emission computed tomography (SPECT), Maron and 
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colleagues (Maron et al., 2004a) found that patients with current PD had 
significantly lower 5-HTT binding in the midbrain raphe, the temporal lobes, 
and the thalamus as compared with HV. In contrast, patients with PD in 
remission had normal 5-HTT binding properties in the midbrain and the 
temporal regions, but still a significantly lower thalamic 5-HTT binding. Neu-
meister and colleagues (Neumeister et al., 2004), using PET, have demonstrated 
a marked reduction of 5-HT1A receptor binding in the anterior and posterior 
cingulate cortices, and in the midbrain raphe in patients with PD compared to 
HV. In another PET study, Nash and colleagues (Nash et al., 2008) have 
detected reduced 5-HT1A receptor binding in the raphe region and in the 
amygdala, as well as in the orbitofrontal and temporal cortices in untreated PD 
patients, and still reduced density of 5-HT1A receptors in the raphe and in the 
hippocampus after recovery with an SSRI paroxetine.  
Also gender-dependent differences in 5-HT-ergic function have been found, 
e.g. lower brain 5-HT metabolism in females compared to males was discovered 
in a PET brain imaging study by Nishizawa and colleagues (Nishizawa et al., 
1997). 
 
5-HT and CCK system genes  
The data from twin and family studies suggest an involvement of genetic factors 
in the development of PD with a heritability estimate near 40% (Hettema et al., 
2001). However, the respective genetic substrates are not known and the 
association studies with candidate genes have so far produced mostly negative 
or inconsistent results with only few gene variants in the key neurotransmitter 
systems showing suggestive link to PD phenotypes. The favoured among them 
have been 5-HT-related gene variants, particularly the 5-HTT-linked poly-
morphism (5-HTTLPR) (Maron et al., 2005a), MAO-A gene VNTR 
polymorphism (Deckert et al., 1999; Maron et al., 2005a), 5-HT receptor 1A (5-
HTR1A) (Rothe et al., 2004; Maron et al., 2005a) and 5-HT receptor 2A (5-
HTR2A) (Inada et al., 2003; Maron et al., 2005a) as well as tryptophan 
hydroxylase gene isomer 2 (TPH2) (Maron et al., 2007).  
In respect to CCK genes, some promising, although not always consistent 
associations  with PD have been observed, particularly for a CT repeat 
polymorphism of the CCK2 receptor (CCK2R) gene (Kennedy et al., 1999; 
Hamilton et al., 2001). Maron and colleagues (Maron et al., 2005b) in their 
SNP-array study, have shown no significant associations between several other 
CCK-related polymorphisms and pure PD phenotype, although CCK2R 
polymorphism −215C–A showed an association in the PD group with comorbid 
mood disorders. They also detected an association of CCK1R 246G-A 
polymorphism with the phenotype of comorbid, but not pure PD.  
The laboratory panic challenges have been now applied to test the premises 
of genetic predisposition to panic. Several studies addressed the influence of 5-
HT related gene variants on experimentally induced panic responses as well as 
on treatment effects of 5-HT-ergic antipanic drugs. Most of these studies have 
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focused on the allelic variants of 5-HTTLPR. Schmidt and colleagues (Schmidt 
et al., 2000) have reported that subjects homozygous for the long variant of 5-
HTTLPR were at greater risk for behavioural hyperreactivity to 35% CO2 
challenge than those with short-allele genotypes. On the contrary, in PD patients 
CO2 reactivity was not influenced by 5-HTTLPR genotype (Perna et al., 2004). 
There are also preliminary data suggesting that 5-HTTLPR variance might 
influence the treatment response to a 5-HT-ergic agent in a gender-dependent 
manner both in PD patients and in HV. Perna and colleagues showed that the 
effect of paroxetine on spontaneous PA was significantly lower in female PD 
patients with the S/S genotype in comparison to subjects with L/L or S/L 
genotypes, but not in men (Perna et al., 2005). Also, a gender dependent effect 
of 5-HTTLPR allelic variance on 5-HTP pretreatment modulation of CCK-4-
induced panic was noted (Maron et al., 2004b) where females, but not males, 
with S alleles of the 5-HTTLPR showed a significantly lower panic rate to 
CCK-4. In a recent study of Kellner and colleagues (Kellner et al., 2009), the 
effect of 5-HTTLPR on treatment response was also demonstrated in healthy 
men. Although they did not detect the expected difference in panic response to 
CCK-4 between L/L and S/S genotypes after placebo-pretreatment, CCK-4-
induced panic after pretreatment with ESC was significantly more pronounced 
in healthy males with 5-HTTLPR S/S genotype.  
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AIMS OF THE STUDIES 
 
The general objective of the present work was to study the modulating role of 
the 5-HT system on CCK-4-induced panic response. Apart from the effects of 
direct pharmacological manipulation of synaptic 5-HT levels, some factors of 
hypothetical importance, such as gene polymorphisms and binding properties of 
5-HT transporter system were investigated. 
 
The specific aims and hypotheses of conducted studies were as follows: 
 
1.  To establish the effect of TD on CCK-4-induced symptoms in patients with 
PD who  responded to treatment with an SSRI citalopram.  
 
Our hypothesis was that in treatment-responders the antipanic action of 
citalopram will be reversed by TD, as indicated by a higher rate and greater 
intensity of CCK-4-induced panic attacks under TD condition as compared to 
the control condition (Study 1). 
 
2.  To explore the effects of genetic polymorphisms of nine candidate genes (5-
HTTLPR, MAO-A VNTR, TPH2 rs1386494, 5-HTR1A −1019C–G, 5-
HTR2A 102T–C, CCKR1 246G–A, CCKR2 −215C–A, DRD1 −94G–A and 
COMT Val158Met) previously associated with PD on the susceptibility to 
CCK-4 challenge in healthy subjects. 
 
We hypothesized that the listed genetic polymorphisms will be associated with 
higher intensity of CCK-4-induced panic response in healthy subjects (Study 2). 
 
3.  To assess brain 5-HTT non-displaceable binding potential (BPND) in male 
and female patients with PD and matched healthy controls using PET with a 
tracer [11C]MADAM.  
 
Our hypothesis was that brain 5-HTT BPND will differ between PD patients and HV 
reflecting the differences in 5-HT system between these two groups (Study 3). 
 
4.  To assess the effect of 6-week treatment with an SSRI escitalopram on 
CCK-4-induced symptoms in HV, who previously responded to CCK-4 
challenge with a panic attack.  
 
Our hypothesis was that in CCK-4 sensitive HV the effect of CCK-4 challenge 
will be attenuated, as indicated by a lower rate and intensity of CCK-4-induced 
panic attacks, after 6-week treatment with escitalopram as compared to the 
placebo (Study 4). 
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MATERIALS AND METHODS 
 
All studies were conducted at the Department of Psychiatry of the University of 
Tartu (Tartu, Estonia). PET and MRI scans were performed in Turku PET 
Centre (Turku, Finland). 
 
 
Ethical considerations 
 
All study protocols and informed consent forms were approved by the Human 
Studies Ethics Committee of the University of Tartu (Tartu, Estonia), and for 
Study 3 also by the Human Studies Ethics Committee of the University of 
Turku (Turku, Finland). All participants provided written informed consent.  
 
 
Subjects 
 
Study 1 The inclusion criteria for the treatment phase were current DSM-IV 
diagnosis of PD (APA, 1994) and absence of current psychiatric or somatic 
comorbidity. Treatment response criteria were panic-free status for at least 2 
weeks and a rating of “much” or “very much improved” on the Clinical Global 
Impression Improvement (CGI-I) scale (Guy et al., 1976) by the 10th week of 
treatment maintained throughout the experimental phase of the study. Treatment 
responders were included in the experimental part of the study while continuing 
citalopram treatment. In total, 18 responders (6 males, 12 females, mean age 
34.5±9.3) were included in this study. Among them, 72% had concurrent 
agoraphobia and 44% had a history of major depression. For other key clinical 
characteristics see Table 1 (Paper I). 
Study 2 The study sample consisted of 110 HV (47 males and 63 females; 
mean age 22.2±5.2) recruited by a flyer advertisement. The inclusion criteria 
were: age between 18 and 50 years, no personal or family psychiatric history, 
and healthy physical status as determined by medical history and physical 
examination. None had a positive urine test for psychoactive drugs at the time 
of a screening. All female participants had a negative urine pregnancy test. All 
participants were required to abstain from alcohol or any medications for at 
least 2 weeks before the study. None of the subjects had participated in previous 
CCK-4 challenge studies. 
Study 3 Eleven medication-free outpatients with PD (5 males, 6 females; 
mean age 31.1±8.6) and 24 HV (12 males, 12 females; mean age 36.9±6.9) 
were included. All were Caucasians, right-handed and in good physical health 
as confirmed by medical history, physical examination, routine blood tests and 
magnetic resonance imaging (MRI) of the brain at 1.5 T. The patients were 
recruited at the Psychiatry Clinic of the Tartu University Hospital. Three 
patients met criteria for current mild depressive episode considered secondary 
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to PD, and one patient had comorbid social anxiety disorder. Healthy subjects, 
matched to the patients by age and sex, were recruited by newspaper advertise-
ments in Tartu, Estonia and in Turku, Finland. Only those HV without personal 
or family (defined as first-degree relatives) history of psychiatric disorders were 
included in this study. All participants abstained from alcohol and benzo-
diazepines for at least 2 weeks prior to PET scans as confirmed by questioning 
and medical records. None of them were heavy smokers or had current or 
lifetime diagnosis of alcohol dependence or abuse. None of the subjects had 
taken any antidepressant or other medication known to affect 5HTT binding for 
at least 4 months before the study. 
Study 4 The study consisted of two phases with separate protocols. From the 
total of 82 subjects (29 men, 53 women; mean age 22.3 ± 5.0), who underwent a 
challenge with intravenous CCK-4 (50 µg), 37 (45.1%) experienced a pre-
defined PA and were asked to participate in the second phase of the study, 27 of 
them agreed. In the course of the study phase II, 4 volunteers dropped out: one 
male and 2 females due to side-effects of study drug; one female due to an un-
expected pregnancy. Treatment non-compliance was detected in four subjects, 
whose data were omitted from further analysis. To maintain the comparability 
of groups the data of one female in Dp group (order of treatments – Drug, 
followed by placebo) with uncommonly high baseline VAS anxiety score prior 
to the first challenge was also excluded. Thus, the data of 18 subjects (10 males, 
8 females, mean age 22.5 ± 5.8) were included in final analysis: 11 subjects in 
the Dp group (45% male; mean age 22.9 ± 6.1), and 7 in the pD group (order of 
treatments – placebo, followed by Drug) (71% male; mean age 22.4 ± 6.1).  
 
 
Assessments 
 
The diagnostic assessments in all studies were done by experienced psychiat-
rists using the Estonian translation of a structured diagnostic instrument, the 
Mini International Neuropsychiatric Interview - M.I.N.I. 5.0.0 (Sheehan et al., 
1998).  
In all the challenge studies (Studies 1, 2, 4) the subjective effects of CCK-4 
challenge were assessed with a set of Visual Analogue Scales (VAS), based on 
the scales of Bond and Lader (Bond & Lader, 1974) consisting of 100-mm lines 
for the dimensions of anxiety (VAS-A), feeling of overall discomfort (VAS-D) 
and the similarity of the experience to spontaneous PA (VAS-S) (the latter 2 
only in Study 1). CCK-4-induced symptoms were rated on the Panic Symptom 
Scale (PSS; (Bradwejn et al., 1991)) assessing the intensity of 18 symptoms 
derived from the DSM-IV criteria for a PA from 0 (not present) to 4 (extremely 
severe). Measures derived from the PSS were the number of symptoms scored 
at least 1, sum intensity score, defined as the sum of all individual item ratings, 
and subscale scores for somatic and cognitive symptoms. 
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The arterial blood pressure (BP) and heart rate (HR) were measured with an 
automatic sphygmomanometer (Dinamap Pro 100, Criticon, Tampa, FL, USA). 
Maximum changes in the studied parameters were calculated by subtracting 
baseline scores from the highest value obtained within 120 s after injection.  
Study 1 The treatment response was assessed with the CGI (Guy et al., 
1976) and Panic Disorder Severity Scale – PDSS; (Shear et al., 1997). For the 
assessment of mood and generalized anxiety symptoms, the Montgomery–
Åsberg Depression Rating Scale (MADRS; (Montgomery & Asberg, 1979)), 
Beck Depression Inventory (BDI; (Beck et al., 1961)) and Hamilton Anxiety 
Rating Scale (HAS; (Hamilton, 1969)) were used. The a priori criteria for the 
occurrence of a PA were: (a) sudden onset of at least four panic symptoms; (b) 
anxiety/apprehension/fear PSS item scored at least 2; (c) at least moderately 
severe (>35%) anxiety or fear on VAS-A; and (d) at least moderate (>35%) 
similarity of experience to spontaneous PA on VAS-S.  
Study 3 On the day of PET scan, the patients were assessed with the PDSS; 
(score range 0–28) (Shear et al., 1997) and with the Hamilton Anxiety Rating 
Scale (HAS; score range 0–42; (Hamilton, 1969)). 
Studies 2&4 The baseline anxiety and depression were evaluated by 
Hamilton Anxiety Rating Scale (HAS; (Hamilton, 1969)) two subscales of the 
self-rated Emotional State Questionnaire (EST-Q; (Aluoja et al., 1999)) and 
VAS-A. The a priori criteria for the occurrence of a PA were: (a) sudden onset 
of at least 4 PSS panic symptoms, with at least moderate intensity (PSS score 
2); (b) PSS item anxiety/apprehension/fear scored at least 3 (severe). In Study 2 
additionally a net increase equal or greater than 50 mm on VAS-A was 
requested.  
 
Substances  
 
The CCK-4 (Trp-Met-Asp-Phe-NH2) (Clinalfa, Merck Biosciences AG, 
Switzerland) (Studies 1, 2, 4) was diluted in sterile physiological solution before 
the challenge, and 25 μg (Study 1) or 50 μg (Studies 2, 4) of CCK-4 was used 
for the challenge as a bolus injection via an intravenous cannula. 
Study 1 Citalopram (CIT) was used as Cipramil® (H. Lundbeck A/S, 
Denmark) in 20mg tablets. Amino acids were obtained from SHS International 
Ltd (UK) and prepared as described by Young and colleagues (Young et al., 
1985).  
Study 3 The precursor N-desmethyl-MADAM and MADAM were obtained 
from PharmaSynth AS, Tartu, Estonia. [11C]Methane was produced at the 
Accelerator Laboratory of Åbo Akademi with a 103-cm isochronous Efremov 
cyclotron using the 14N(p,a)11C reaction. Highly specific radioactivity 
[11C]methyl iodide was prepared from [11C]methane. The preparation of 
[11C]MADAM from [11C]methyl triflate was performed according to a 
published procedure with minor modifications (Halldin et al., 2005). 
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Study 4 Escitalopram was used as Cipralex® (H. Lundbeck A/S, Denmark) 
in 5 mg (1st week) and 10 mg (the rest of 6 weeks) tablets. Placebo tablets, 
identical in size and colour as well as a standard ESC used for the assessment of 
ESC plasma concentrations were the courtesy of H. Lundbeck A/S, Denmark. 
 
 
Treatments 
 
Study 1 The patients were treated with a flexible dose of CIT (mean final dose 
of CIT was 18.9±4.4 mg/day; range 10–30 mg/day) for 10 weeks. The dose of 
CIT was 10 mg/day for the first week and then optimized according to response 
and tolerability. Alprazolam (0.25–0.5 mg/day) was used in three patients for 
the first 2–4 weeks due to an initial increase in anxiety.  
Study 4 Subjects enrolled in the second phase of the study were randomized 
to two groups. One group (group Dp; D – Drug, p – placebo) received ESC for 
6 weeks (5 mg/day for one week and then 10 mg/day) and, after a 1-week 
washout period, placebo for another 6 weeks. The other group (group pD) 
received placebo first and then, after a 1-week washout, was switched to ESC. 
Each treatment period was concluded by a challenge with CCK-4 (50 µg). 
 
 
Procedures  
 
Study 1 TD/CCK-4 challenges were carried out in a double-blind, placebo-
controlled, balanced crossover design, with each patient taking part in two 
similar test days. Test days were about 1 week apart (mean 9 days; range 5– 
20 days), the first day approximately during the 11th week (between days 74 
and 105) and the second day approximately during the 12th week (between days 
81 and 112) of the study. Patients had a tryptophan-free amino-acid drink on the 
depletion day and a drink containing tryptophan on the control day. The order 
of the drinks was randomly allocated. The TD test was carried out according to 
a standard protocol (Young et al., 1985). Patients followed a 24-h low 
tryptophan diet on the day before the test and fasted starting at midnight on both 
test days.  
On the test day, patients arrived at the research unit at 8:00 A.M. During the 
procedure, they stayed in the same room lying on a bed or sitting and were 
allowed to drink only water. At 8:20 initial assessments were made, baseline 
values of BP, HR and VAS-A were registered and blood samples for baseline 
levels of TRP and LNAA were obtained. At 8:30, subjects consumed the amino 
acid or control drink. BP, HR and VAS-A were registered in 2-h intervals. At 
1:00 P.M., the intravenous cannula was inserted into an antecubital vein and 
saline infusion was started. After pre-challenge assessments, at 1:20, the blood 
sample for the TRP and LNAA assay was drawn through the cannula. At 1:30, 
after registration of BP, HR and VAS-A, a bolus injection of CCK-4 (25 μg) 
was given through the cannula. BP, HR and VAS-A were registered in 30-s 
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intervals for 2 min and at 5 and 15 min after CCK-4 injection. After CCK-4-
induced symptoms had abated, patients’ peak symptoms were rated with the 
PSS, VAS-A, VAS-D and VAS-S. After completion of the last measurements, 
the cannula was removed and the patient allowed to leave when comfortable 
and given an option of phone contact in the next 24 h. 
Study 3 The radioligand used in this study for imaging of 5-HTT binding 
was [N-methyl-11C]N,N-dimethyl-2-(20-amino-40methylphenyl-thio)ben-
zylamine ([11C]MADAM) (Lundberg et al., 2005). PET experiments were 
conducted using a brain-dedicated, high-resolution PET scanner HRRT 
(Siemens Medical Solutions, Knoxville, TN) as previously described (Hirvonen 
et al., 2008). Briefly, after a transmission scan was performed with a caesium-
137 point source, emission data were collected after radioligand injection for 75 
minutes using 17 frames (3x1, 4x3, and 10x6 min) in list mode. Images were 
reconstructed into 1.2x1.2x1.2 mm3 volumes using speed-optimized OP-OSEM-
3D (Ordinary Poisson-OSEM in full 3D) reconstruction. The head was fixed 
using an individually moulded thermoplastic mask. The antecubital vein was 
cannulated and 400–500 MBq [11C]MADAM was injected as a rapid bolus 
flushed with saline. Injected mass and specific radioactivity for HV and patients 
with PD were 0.59±0.40 vs. 0.72±0.54 mg, and 284.6±117.1 vs. 270.6± 
149.0 MBq/ nmol, respectively, with no statistically significant differences 
between the groups in any variable. Radiochemical purity was >98%. 
Studies 2&4 Upon arrival at the research unit at about 10 A.M. on challenge 
days the subjects completed the EST-Q and HAS. An intravenous cannula was 
inserted into an antecubital vein and saline infusion started to keep the cannula 
open. The subjects stayed in the same room resting. At 11 A.M., after the 
registration of baseline values of BP, HR and VAS-A, a bolus injection of 50 µg 
of CCK-4 was given through the cannula (during ca 3 seconds). The subjects 
were asked to describe any symptoms they experienced after the injection. The 
BP, HR and VAS-A were registered every 30 seconds for 2 minutes, then at 5 
and 15 minutes. After the CCK-4-induced symptoms had abated, the subjects 
were assessed on PSS and rated VAS-A for the peak symptoms. After 
completion of the last measurements the cannula was removed and the subject 
was allowed to leave when comfortable with an option of phone contact over 
the next 24 hours.  
For genotyping, the blood samples were obtained (Studies 2&4; for further 
details see chapter ”Laboratory analysis”). 
To check for compliance with study medication, samples were collected 
from every subject at four time points (one sample on each challenge day and 
one on randomly chosen visit during each treatment period) (Study 4).  
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Laboratory analyses 
 
Study 1 Plasma free- and total tryptophan (TRP) were measured by isocratic 
high-performance liquid chromatography (HPLC) with UV end-point detection. 
The inter- and intra-assay coefficients of variation (CV) were 9% and 5.2% 
(n=9) and 13.5% and 6.9% (n=5) for the total and free TRP respectively. Large 
chain amino acids (LNAA) were measured by gradient-elution HPLC with 
utilization of fluorescence end-point detection. The amino acid residues were 
derivatised pre-column to enhance the detection signal. Validation analysis 
showed that the CV over the range of the standard amino acid standard curves 
was <14% for all acids of interest. 
Study 2 Nine candidate genes were selected for this study based on the 
previous positive findings from genetic association studies in PD (Table 1, 
Paper II). DNA was extracted from 5ml of venous blood using a standard 
phenol–chloroform extraction. Genotyping of genetic polymorphisms in 5-
HTTLPR, MAO-A VNTR, and TPH2 rs1386494 loci was performed as 
described previously (Lesch et al., 1996; Sabol et al., 1998; Maron et al., 2007). 
For oligonucleotides used to get amplicons that contain respective poly-
morphisms in 5-HTR1A 1019CG (rs6295), 5-HTR2A 102TC (rs6313), CCKR1 
246GA, CCKR2 215CA (rs1799721), DRD1 94GA (rs5326) and COMT 
Val158Met (rs4680) loci refer to Paper II. Amplification was followed by 
digestion with restriction endonucleases and agarose gel electrophoresis. 
Restriction endonucleases were used from Fermentas (see paper II). For all 
genotypes tested, 25 samples were genotyped twice and no discrepancies were 
found. 
Study 4 Plasma ESC concentrations were assessed using the ultra high 
performance liquid chromatography-mass spectrometry (UHPLC) system 
(Agilent Series 1290 Infinity LC, Santa-Clara, CA, USA), in two samples 
collected during the treatment period with an active substance, and in one 
randomly chosen sample collected during the placebo treatment period, after the 
study had ended. For genotyping, the blood samples were obtained, DNA 
extracted and 5-HTTLPR genotype determined as described by Maron et al 
(Maron et al., 2004b).  
 
 
Statistical analysis 
 
Study 1 The data were analysed using the software package STATISTICA 5.1 
(StatSoft, Tulsa, OK, USA). The Wilcoxon matched-pairs test and Mann–
Whitney U test were used to analyze the nonparametric data. The proportions 
were compared by Pearson Chi-square tests. One-way analysis of variance 
(ANOVA) was used to compare the cardiovascular responses to CCK-4 
injection between TD and placebo groups. The data were presented as mean 
values and standard deviation (SD). The sample size of 18 subjects allowed 
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detection of a 50% change in panic rate with 90% power at a significance level 
of 5%. 
Study 2 The genotype and allele frequencies between the panic and 
nonpanic groups were compared by chi-square tests using the software package 
STATISTICA 5.1. Odds ratio (OR) values and 95% confidence intervals (CI) 
were calculated using STATA 6.0. The results were considered nominally 
significant at the level of p<0.05 without correction for multiple comparisons. 
Study 3 Image analysis and modelling of [11C]MADAM kinetics 
[11C]MADAM PET images were corrected for frame misalignment and co-
registered with T1-weighted MR images as previously described using SPM2 
(Hirvonen et al., 2008).  Volumes of interest (VOIs) were manually delineated 
on co-registered T1-weighted MR images using Imadeus software (version 1.2, 
Forima Inc., Turku, Finland). The following VOIs were drawn: dorsal, ventral 
and subgenual anterior cingulate cortex; dorso- and ventrolateral and medial 
prefrontal cortex; lateral and medial orbitofrontal cortex; angular and supra-
marginal gyri; superior, middle and inferior temporal gyri; anterior and 
posterior insular cortex; hippocampus and amygdala; dorsal caudate, dorsal 
putamen, ventral striatum, and thalamus; dorsal raphe nuclei; grey matter of 
cerebellum. Regional time-activity curves were derived within these VOIs from 
the dynamic PET images. Specific binding of [11C]MADAM was estimated as 
BPND, which is the ratio at equilibrium of specific binding to non-displaceable 
uptake (Innis et al., 2007). BPND was estimated using the simplified reference 
tissue model with the cerebellum as reference region (Lammertsma & Hume, 
1996; Lundberg et al., 2005). Prior to modelling, time-activity curves were 
weighted according to frame duration and counts in frame (Hirvonen et al., 
2003).  
Voxel-based analysis To confirm the results from the regional analysis, we 
conducted voxel-based analysis on parametric BPND maps using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8) (Friston KJ et al., 1995). 
Parametric BPND maps were first calculated using the basis function imple-
mentation of the simplified reference tissue model (Gunn et al., 1997). These 
parametric maps were then spatially normalized using transformation para-
meters that had been estimated from summed PET images and an in-house 
ligand-specific template for [11C]MADAM. Spatially normalized parametric 
BPND maps were then smoothed with a 12-mm (FWHM) Gaussian kernel. 
Group differences were estimated with a voxel-wise independent samples t-test. 
Statistical significance in the exploratory analysis was inferred as t<2.4 at voxel 
level and corrected p<0.05 at cluster level. 
Statistical analysis Statistical analysis was carried out using SPSS 13.0 for 
Windows (Release 13.0.1, copyright SPSS Inc., 1989–2004). BPND data was 
modelled by means of repeated measures analysis of variance (rmANOVA), 
with group status and sex as between-subject predictors, brain region as a within 
subject predictor, and age as a covariate. The interaction term group x sex x 
region was used to assess region-specific and sex-dependent group effects, 
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while the interaction term group x sex assessed sex-dependent group effects 
across brain regions, effectively avoiding the problem of multiple comparisons. 
Finally, group differences were assessed in each brain region using post hoc t-
tests. The associations between BPND and symptom ratings were assessed using 
Pearson product-moment correlation coefficients (R). The correlation analysis 
was exploratory and its results not considered primary due to the small sample 
size for each gender. To control for positive bias due to violation of the 
sphericity assumption associated with interaction terms including within-subject 
factors with three or more levels, degrees of freedom in the averaged tests of 
significance were adjusted using the Greenhouse–Geisser method. Observed p-
values were corrected for multiple comparisons using the false discovery rate 
(FDR) method, which keeps the overall proportion of false positives below 0.05 
(Benjamini & Hochberg, 1995). 
Study 4 To assure comparability of the groups we used Fisher exact test, t-
tests and Wilcoxon rank-sum tests as appropriate. The effect of treatment was 
estimated using random intercept models. At first, the results of the second and 
third challenges were compared. Thereafter the data of the first challenge were 
taken into account by subtracting these from the readings of response variables 
of second and third challenges. In both models, the time effect (time measured 
as provocation serial number), drug effect and the carry-over effect as 
interaction of both were estimated. Additionally, main effect of genetic 
variation of 5-HTTLPR polymorphism with three levels (SS, SL, LL) and the 
interaction between the genetic variation and treatment were estimated. Similar 
analysis was applied to gender effect. For PA intensity, HAS, and EST-Q 
anxiety scores the generalized mixed models were used; for the rest of the 
variables, linear mixed models were used. Baseline diastolic BP and baseline 
VAS anxiety score were transformed to have a normal distribution. For the 
effect sizes, 95% confidence intervals were calculated. Statistical software R 
version 2.9.0 with lme4 package was used. 
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RESULTS AND DISCUSSION 
 
Study 1. The effect of tryptophan depletion on response to CCK-4 challen-
ge in patients with panic disorder after treatment with citalopram. 
Plasma tryptophan levels. There were no significant differences in baseline 
measures of plasma tryptophan between TD and control days. Five hours after 
ingestion of the TRP-depleted mixture, there were drops of 73% and 69% in 
mean values of total and free plasma TRP, respectively. After the control drink, 
mean plasma levels of free and total plasma TRP increased 369% and 138%, 
respectively. The mean TRP/LNAA ratio decreased 92% on the TD day and 
46% on the control day (Table 2, Paper I). These data indicated that TD 
effectively decreased the availability of TRP in the brain.  
Pre-challenge effects. TD did not cause any significant changes in psycho-
logical and cardiovascular measures, the pre-challenge baseline variables were 
similar on the two test days (Table 3, Paper I). 
Post-challenge effects. CCK-4 challenge caused a PA in about 1/3 of the 
patients on both TD and control days (n=5, 27.8% and n=6, 33.3%, respec-
tively; χ2=0.13, df=1, p=0.72). Neither the PSS sum intensity score nor 
cognitive or somatic subscores were significantly affected by TD (Figure1). The 
mean maximum ratings of VAS-A and VAS-D did not differ significantly 
between the two test days. The changes in BP and HR values were also similar 
on the two test days (Table 4, Paper I). A secondary analysis with a breakdown 
by gender did not reveal any significant differences in panic rate between TD 
and control days. 
Further examination of the results, applying more stringent criteria for 
treatment response (panic-free status for at least 2 weeks plus at least 50% 
decrease on the PDSS maintained throughout the experimental phase; n=14) 
and in a subset of patients in full remission (panic-free status plus PDSS score 
≤3, with no score >1 on any PDSS item; n=8), no differences were revealed 
between the TD and control conditions in any of the psychological or 
cardiovascular measures. 
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Figure 1. Intensity of panic symptoms on PSS (mean scores) 
Abbreviations: TD Tryptophan depletion, PSS Panic Symptom Scale, Tot Total score, 
Som Subscore of somatic symptoms, Cog Subscore of cognitive symptoms 
 
 
Discussion. The results of this study showed that an acute lowering of brain 5-
HT availability by TD did not affect the behavioural or cardiovascular response 
to CCK-4 challenge in PD patients who responded to a 10-week treatment with 
an SSRI CIT. A nearly 30% panic rate, similar to what was previously observed 
with CCK-4 challenge after an SSRI treatment in patients with PD (Shlik et al., 
1997; van Megen et al., 1997) implies that the sensitivity to CCK-4 challenge 
was effectively decreased by treatment with CIT in this study. The lack of the 
effect of TD in our study was at odds with previous findings of Bell and 
colleagues (2002), demonstrating that TD reversed the protective effect of 
treatment with another SSRI, paroxetine, in panic challenge with flumazenil. 
Thus, the reduced sensitivity to CCK-4 after SSRI treatment may be related to 
mechanisms other than 5-HT availability in the brain and the effects of CCK-4 
and flumazenil may be modulated differently by 5-HT.  
In addition to studies showing the reduction of the CCK-4 sensitivity as a 
result of treatment with serotonergic antidepressants (Bradwejn & Koszycki, 
1994b; Shlik et al., 1997; van Megen et al., 1997), assumingly increasing the 
level of synaptic level 5-HT, it has been observed that in HV, an acute pre-
treatment with 5-HT precursor 5-hydroxytryptophan (5-HTP) significantly 
reduced manifestations of CCK-4-induced panic, particularly in females (Maron 
et al., 2004c). Considering the hypothesis of a panic-restraining nature of 5-HT 
(Deakin & Graeff, 1991), it seemed plausible that a reduction in the 5-HT levels 
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would lead to an increased CCK-4 sensitivity. These interactions, however, may 
be more complex. 
Koszycki and colleagues (1996) have shown that, without influencing the 
panicogenic effect of CCK-4, TD augmented CCK-4-induced release of 
adrenocorticotropic hormone, cortisol and prolactin in healthy males. These 
findings suggest that 5-HT systems may have a role in the neuroendocrine, but 
not the psychological, actions of CCK-4. Subsequently, Depot and colleagues 
(1999) reported that acute administration of ondansetron, a selective 5-HT3-
receptor antagonist, significantly decreased CCK-4-induced panic in healthy 
males and reduced cortisol, growth hormone and prolactin response. Thus, at 
least in regard to 5-HT3 receptors, a reduction rather than an increase in 5-HT 
effects was associated with the alleviation of CCK-4-induced panic. Further-
more, these effects dissipated upon chronic treatment with ondansetron, 
indicating that adaptive changes that abolish the initial effect are likely to occur. 
One explanation for our findings is that the SSRIs may alter the CCK 
transmission system, perhaps through desensitisation of the postulated CCK-2R 
receptor hypersensitivity (Bradwejn & Koszycki, 1994a), where variation in 
CCK-2R sensitivity may also explain the difference in panicogenic properties of 
CCK-4 between PD patients and HV (Bradwejn et al., 1991). Increasing brain 
5-HT leads to an increased release of brain CCK (Raiteri et al., 1993; Rosen et 
al., 1995), which might over time down-regulate CCK receptors. Thus, one 
theory is that while SSRIs initially increase CCK as a result of making more 5-
HT available, perhaps explaining the early worsening seen with these drugs in 
some patients, the later desensitization of CCK-2R is independent of 5-HT 
availability in the synaptic cleft. Such an explanation is compatible with the 
preclinical data on SSRI administration, which shows an initial increase in CCK 
transmission and the number of CCK receptors (Rosen et al., 1995; Koks et al., 
1999). These effects apparently normalize upon chronic treatment, as 
demonstrated by Harro and colleagues (1997), who found no changes in the 
density of CCK receptors or in the content of CCK-related peptides after long-
term treatment with various antidepressants, including 5-HT reuptake inhibitors. 
If the sensitivity of CCK-2R, and not the synaptic availability of 5-HT, is a 
critical factor determining the reactivity to a CCK-4 challenge, then effects of 
acute TD on CCK-4 sensitivity would not be as strong as the effects seen with 
other challenge agents in both HV (Goddard et al., 1995; Klaassen et al., 1998; 
Miller et al., 2000) and, even more robustly, in PD patients (Kent et al., 1996; 
Miller et al., 2000; Schruers et al., 2000) and those in remission (Bell et al., 
2002). This hypothesis also fits with the above-mentioned study by Koszycki 
and colleagues (1996) showing that TD did not influence the panicogenic effect 
of CCK-4 in HV.  
Among the other limitations of our study, it should be noted that the mean 
TD-induced decrease in free plasma TRP remained just below 70%, whereas, a 
more robust depletion may have been needed to elicit behavioural effects. Also, 
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this study had statistical power to detect only a large, 50% difference in panic 
rate; a bigger sample size would have been required to find a smaller effect. 
 
Study 2. Association testing of panic disorder candidate genes using CCK-4 
challenge in healthy volunteers. 
After CCK-4 challenge, 39 (35.5%) subjects of 110 experienced a PA, while 71 
subjects were defined as non-panickers. The descriptive data on panic and 
anxiety variables by groups are presented in Table 2 (Paper II). Two CCK 
receptor gene polymorphisms, CCK2R −215C–A and CCK1R 246G–A, were 
excluded from association analyzes after genotyping due to absence of subjects 
with A alleles in both SNPs in our sample. The distributions of genotypes for all 
polymorphisms included in the analyses did not deviate from Hardy–Weinberg 
equilibrium (p=0.11–1.00). The genotype frequencies of 5-HTTLPR, MAO-A, 
5-HT1A, 5-HT2A, DRD1 and COMT polymorphisms are shown in Table 3 
(Paper II) and the allelic and genotypic distributions of TPH2 gene are 
presented in Table 4 (Paper II).  
There were no differences in the distribution of 5-HTTLPR genotypes and 
allele frequencies between panic and non-panic groups. There were no 
associations between panic rate and genotypes of 5-HTTLPR separately in 
females. Of note, the subjects with LL genotype demonstrated significantly 
higher level of baseline anxiety measured by VAS immediately before CCK-4 
injection than the carriers of S alleles (LL: 12.1±10.7, LS: 7.7±7.6, SS: 5.4±7.2; 
F(2.11)=4.2; p=0.02). None of other measurements of anxiety or panic 
responses were associated with 5-HTTLPR polymorphism.  
The comparisons of MAO-A promoter region variants between the groups 
were made according to functional classification of Sabol et al (1998). There 
were no significant differences in genotype or allele frequencies of MAO-A 
promoter region polymorphism between the panic and non-panic groups. 
Separate analysis of this polymorphism in females did not show any significant 
difference in genotype frequencies of MAO-A promoter region polymorphisms 
between groups (p=0.44). VNTR polymorphism of MAO-A did also not 
associate with any other anxiety or panic variables.  
There were significant differences for both genotypic and allelic frequencies 
of rs1386494 A/G SNP of TPH2 gene between panic and non-panic groups with 
the frequencies of G/G genotype (p=0.03) and G allele (p=0.009) significantly 
higher in panickers (Table 1). Further analysis showed significant difference in 
genotypic and allelic frequencies of this SNP between panic and non-panic 
groups in females (p=0.038 and p=0.048, respectively), but not in males 
(p=0.26 and p=0.09, respectively). No associations between any other variables 
of anxiety or panic symptoms and rs1386494 A/G SNP were observed.  
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Table 1. Distribution of genotypes and allele frequencies of TPH2 1386494 A/G poly-
morphism 
 
 GENOTYPE FREQUENCIES 
(%)
ALLELE FREQUENCIES 
(%) 
 GG AG AA G A 
Non-panic 74.7 23.9 1.4 86.6 13.4 
Panic 94.9 5.1 0 97.4 2.6 
 
 
Finally, no significant differences were found between panickers and non-
panickers in genotypic or allele distributions for any other studied candidate 
gene polymorphisms. Subsequent analysis showed that the subjects with CC 
genotype of 5-HT1A −1018 polymorphism demonstrated higher cognitive 
symptoms on the PSS (4.8±2.9) then carriers of CG (3.4±2.6) or GG (3.5±1.8) 
genotypes (F(2.11)=3.5; p=0.03). The subjects with TT genotype of 5-HT2A 
102 polymorphism demonstrated higher increase on the VAS after CCK-4 
injection (78.5±15.6) then carriers of CT (61.0±22.9) or CC (65.0±20.3) 
genotypes (F(2.11)=3.1; p=0.049).  
 
Discussion. The results of this study revealed that the TPH2 rs1386494, but 
none of other polymorphisms previously implicated in PD, is possibly 
associated with CCK-4-induced panic in HV.  
This finding is intriguing in light of predominant expression of TPH2 in the 
brain stem, the major locus of the 5-HT-producing neurons (Zill et al., 2004b) 
and the proposed role of 5-HT in the pathogenesis of PD (Maron & Shlik, 
2005). An increased level of 5-HT synaptic concentration may be a necessary 
factor of antipanic effect of SSRIs and particularly for their potency to reduce 
the occurrence of PA (Nutt, 1998). However, acute lowering of brain 5-HT 
availability with TD did not modify the reduced sensitivity to CCK-4 challenge 
in PD patients effectively treated with CIT (Tõru et al., 2006). Previously, 
Maron and colleagues have demonstrated that acute administration of 5-HT 
precursor, 5-HTP, significantly reduced the rate of CCK-4-induced PA in 
healthy females (Maron et al., 2004c). Subsequently a positive association 
between rs1386494 polymorphism of TPH2 gene in a subgroup of female PD 
patients without affective comorbidity was observed (Maron et al., 2007). 
Particularly, the frequencies of the both G/G genotype and G allele were 
significantly lower in females with pure PD as compared to healthy females, 
whereas this association was not seen in the total female group or in the 
subgroup of PD females with major depression. On the contrary, Zill and 
colleagues (2004a) recently demonstrated the positive association between 
rs1386494 SNP and major depression with greater prevalence of the G allele in 
patient groups. In the present study, the HV categorized as panickers had 
significantly higher frequencies of G/G genotype and G allele than those with 
less panic response to CCK-4 challenge. Importantly, the association between 
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rs1386494 polymorphism and CCK-4-induced panic was also seen in females 
similarly to our previous finding in PD female patients. However there was lack 
of associations between this SNP and panic or anxiety severity on the used 
scales, probably due to differences between categorical and dimensional 
assessments of panic responses. Notably, the association of rs1386494 
polymorphism with PA rates remained significant when panickers were 
compared to the subjects with very weak response to CCK-4 challenge (n=21) 
who did not meet PA criteria and had anxiety net increase less than 50mm on 
the VAS scale (p=0.03 for genotypes and p=0.005 for alleles). 
Nevertheless the divergence in allelic distributions and associations with PD 
phenotype in patient group and CCK-4-induced PA in HV indicate that further 
investigations on the functional effects of rs1386494 polymorphism are needed.  
Lim and colleagues (2006) have examined the presence of functional or cis-
acting polymorphisms in the TPH2 gene that may affect mRNA expression. 
Their analysis of allele-specific expression of TPH2 mRNA in sections of 
human pons revealed several SNPs for which heterozygosity was highly 
correlated with allelic expression imbalance and overall expression of TPH2 
mRNA. Although identified SNPs are closely linked to rs1386494 poly-
morphism, the last variant itself was not associated with allelic mRNA 
expression of TPH2. Further, Chen and colleagues (2008) reported that the 
polymorphisms within the 5’ regulatory region play an important role in the 
regulation of TPH2 gene expression. Particularly they found that 90A/G 
(rs11178998) polymorphism affects, in most cases up-regulates, gene 
expression at both transcriptional and post-transcriptional levels, whereas the 
regulation of gene expression by this SNP is apparently cell-specific.  
The findings of the present study did not confirm our earlier preliminary 
evidence of the associations between 5-HTTLPR and panic responses to CCK-4 
challenge test in smaller sample of HV (Maron et al., 2004b). Particularly, we 
have found that healthy females with the LL genotype were more sensitive to 
CCK-4-induced PA than those carrying the S allele. Pertinently, only our group 
has also demonstrated a positive association between longer variations of 5-
HTTLPR and PD phenotype in the patients, most of them with affective or 
anxiety comorbidity (Maron et al., 2005a). Earlier Schmidt and colleagues 
(2000) have reported that subjects homozygous for the L-variant were at a 
greater risk for behavioural hyper-reactivity to 35% CO2 challenge than those 
with S-allele genotypes. On the contrary, in patients with PD, CO2 reactivity 
was not influenced by 5-HTTLPR genetic variants (Perna et al., 2004). Our 
current larger study did not confirm the major role of 5-HTTLPR in 
panicogenesis, at least in a laboratory panic with CCK-4. However, there was 
some evidence of a link of this polymorphism to anxiety manifestations, as the 
subjects with LL genotype had higher anticipatory anxiety preceding CCK-4 
challenge than those with shorter alleles. Notably, the levels of anticipatory 
anxiety did not significantly differ between panickers and non-panickers at the 
baseline and did not predict the occurrence of PA.  
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Other candidate polymorphisms, including MAO-A VNTR, 5-HT1A −1018, 
DRD1 −94 and COMT Val158Met, were also unrelated to occurrence of PA in 
the present study. Furthermore, we were not able to examine the involvement of 
CCK-related polymorphisms, CCK2R −215C–A and CCK1R 246G–A, due to 
absence of rare alleles in our sample. The lack of association between 5-HTR2A 
102T−C polymorphism and CCK-4-induced PA in HV may not be a sufficient 
argument against the involvement of this variant in PD, but may suggest that the 
detected association in PD patients is related to comorbid agoraphobia (Inada et 
al., 2003; Maron et al., 2005a). In our study, the subjects with 102TT genotype 
demonstrated higher net increase of anxiety in response to CCK-4 challenge 
than those with C alleles. This finding at least partly confirms the role of 102T–
C polymorphism in anxiety.  
Various factors need to be taken into account while interpreting the current 
findings and their discrepancies with previous data. The genetic substrates of 
different manifestations of PD, such as PA, anticipatory anxiety or agoraphobia 
may be heterogeneous and affected by environmental factors. The findings from 
previous association studies in PD may have been confounded by a complex 
nature of PD and high prevalence of other psychiatric or somatic morbidity. 
Indeed, most of the polymorphisms explored in this study were previously 
investigated in samples with high prevalence of comorbid disorders, including 
mood and anxiety disorders. Plausibly, more complex clinical phenotypes may 
have stronger genetic substrates than pure panic condition. Although our study 
was conducted in a reasonably large sample of HV, we cannot exclude that 
sample size was not sufficient to detect more subtle associations. The candidate 
polymorphisms in this study were chosen mainly based on our group’s positive 
findings in PD patients. For this reason, and in order to validate previous 
positive associations, we did not correct for multiple testing; however, a 
conservative estimation of significance with correction for multiple compa-
risons would have eliminated the major finding in the TPH2 gene. Notably, 
there are numerous recent investigations on other genetic polymorphisms 
potentially associated with PD (Maron et al., 2008a), which could be candidates 
for further challenge studies.  
In summary, our findings lend tentative support to the possible importance 
of TPH2 rs1386494 SNP in the susceptibility to PA.  
 
Study 3. Gender differences in brain serotonin transporter availability in 
panic disorder. 
The overall rmANOVA showed a highly significant group x sex interaction 
(F=15.93, p<0.001), as well as a significant group x sex x region interaction 
(F=5.51, p=0.015). These effects suggested region-specific and sex-dependent 
group differences in 5-HTT BPND.  
Next, the sex-dependent group differences were modelled in each brain 
region separately. Consistent with the overall analysis, statistically significant 
group x sex interactions specifically in the dorsal anterior cingulate cortex 
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(F=12.20, p=0.002), medial (F=6.59, p=0.016) and dorsolateral (F=10.18, 
p=0.003) prefrontal cortex, anterior (F=7.26, p=0.011) and posterior (F=10.35, 
p=0.003) insula, medial (F=13.39, p=0.001) and lateral (F=7.54, p=0.010) 
orbitofrontal cortex, middle (F=7.75, p=0.009) and superior (F=5.89, p=0.021) 
temporal gyri, angular gyrus (F=10.44, p=0.003), hippocampus (F=4.34, 
p=0.046) and the raphe nuclei (F=7.11, p=0.012) were observed.  
Upon establishing sex-dependent group differences in 5-HTT BPND in 
several brain regions relevant to the pathophysiology of PD, group differences 
in these specific brain areas were estimated in both sexes separately. Consistent 
with region-specific group x sex interactions, male patients with PD 
demonstrated significantly and considerably elevated 5-HTT BPND compared 
with male control subjects in several brain regions, except for the hippocampus, 
which had significantly reduced 5-HTT BPND (Table 2). No statistically 
significant differences between patients with PD and HV were observed among 
females.  
 
 
Table 2. Regional 5-HTT binding potential values in PD patients and healthy controls 
 
 
 
 
Voxel-based analysis of BPND maps confirmed the findings from the regional 
analysis by showing a widespread increase in BPND in males with PD compared 
with male controls (Figure 2, Paper III). Consistent with the regional analysis, 
the largest effect size was found in the left orbitofrontal cortex (data not 
shown). No significant correlations were observed between 5-HTT BPND and 
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clinical scale scores obtained before PET scans neither in total sample nor in 
female PD patients separately. 
In male patients, HAS scores were positively correlated with 5-HTT BPND in 
the dorsal anterior cingulate cortex (R=0.90, p=0.038), dorsal caudate (R=0.94, 
p=0.020), anterior insula (R=0.98, p=0.003), medial frontal cortex (R=0.94, 
p=0.019), and the lateral (R=0.98, p=0.003) and medial orbitofrontal cortex 
(R=0.93, p=0.024). Similarly, PDSS scores were positively associated with 5-
HTT BPND in the ventral anterior cingulate cortex (R=0.96, p=0.010), dorsal 
caudate (R=0.94, p=0.019) and lateral orbitofrontal cortex (R=0.91, p=0.031), 
whereas a negative association was seen in the hippocampus (R= –0.97, 
p=0.006). Notably, the positive correlations were driven by one male subject 
with the highest symptom scores and also highest 5-HTT BPND. 
 
Discussion. The results provided evidence of global changes in 5-HTT density 
in the brain, including the structures implicated in neuronal network of PD in 
males with PD as compared with HV. Specifically, male patients showed a 
higher 5-HTT BPND in the brainstem raphe, temporal gyri, anterior cingulate, 
insular, orbitofrontal, prefrontal and frontal cortices, but lower 5-HTT 
availability in the hippocampus. Thus, a reduced synaptic concentration of 5-
HT in the raphe and several cortical regions, as a result of higher 5-HT re-
uptake, but an elevated 5-HT neurotransmission in the hippocampus, as a result 
of lower 5-HT re-uptake, may together contribute to the manifestation of PD in 
males. 
Such pattern is consistent with the concept of Deakin and Graeff (1991), 
which linked a deficit of 5-HT neurotransmission to panicogenesis and 
proposed a dual role of 5-HT in modulation of different types of anxiety. Our 
findings also suggest that 5-HT-ergic pathways to the hippocampus have 
distinctive impact on the panicogenesis independent from the cortical pathways. 
Similar regional differences were previously observed for  benzodiazepine/ 
GABA-A receptor binding, which was reduced in multiple areas of the frontal, 
temporal, and parietal cortices (Malizia et al., 1998; Hasler et al., 2008), but 
increased in the hippocampus/parahippocampal region in patients with PD 
(Hasler et al., 2008). Pertinently, a recent PET study in male patients with PD 
demonstrated a global reduction of 5-HT1A receptor binding in overlapping 
brain regions (Nash et al., 2008), suggesting that reduced 5-HT neurotrans-
mission via these receptors is one of the pathways contributing to the develop-
ment of PD. This study also demonstrated that males with PD in remission after 
treatment with paroxetine showed normalized density of 5-HT1A postsynaptic 
receptors, but remaining reduction in the density of 5-HT1A receptors in the 
raphe and in the hippocampus, suggesting a trait nature of these alterations. 
According to the Deakin–Graeff hypothesis, the median raphe nucleus – 
hippocampal 5-HT pathway promotes resistance to chronic, unavoidable stress 
via 5-HT1A receptors, whereas failure of this mechanism may lead to depres-
sion. Moreover, the neuronal network between the amygdala, hippocampus and 
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cortical structures may be involved in cognitive attributions of fear stimuli and 
the enhancement of memory function facilitating adaptive responses (Goddard 
& Charney, 1997). Thus, the dysfunction of the 5-HT system in the hippo-
campus in males with PD may reflect an impaired tolerance of or a maladaptive 
responsiveness to stressors. The exact role of the hippocampal 5-HT system and 
its specificity to panicogenesis require further clarification. 
Notably, the present study did not replicate the findings of our earlier 
SPECT study, which showed a reduced 5-HTT binding in the brainstem, the 
temporal lobes and the thalamus of females with PD. As compared with the 
former SPECT investigation, the present PET study had certain advantages, 
including higher resolution, regional volume co-registration and correction by 
MRI, and estimation of 5-HTT binding potential for more brain regions. 
Furthermore, the previously used tracer, [123I]nor-b-CIT, has high affinity to 
both 5-HTT and dopamine transporter, which may have biased the findings for 
brain 5-HTT availability. Importantly, females with PD in the current sample 
had more severe panic and anxiety symptoms on PDSS and HAS than female 
patients in previous sample, which may also account for discrepant results. As 
previously suggested (Maron & Shlik, 2005), the reduced 5-HTT availability in 
females with PD may reflect compensatory processes in the 5-HT system 
leading to mitigation of panic symptoms. If 5-HTT binding potential in PD is 
state-dependent, then such compensation in 5-HTT functioning is perhaps less 
obvious in more severe cases. However, the small sample size is another likely 
reason of the failure to demonstrate significant changes of 5-HTT availability in 
female patients in the present study.   
The results of the present study may help to delineate the functional status of 
the 5-HT system in PD and other neuropsychiatric conditions. Indeed, our 
findings of increased 5-HTT BPND in males with PD are clearly distinguishable 
from available PET studies of 5-HTT in various other neuropsychiatric 
conditions. Notably, all other 5-HTT PET studies have used tracers different 
from ours, mostly [11C]DASB and [11C]McN5652, and most of them were not 
designed to examine the brain 5-HTT density separately in male and female 
subjects. So far, a decreased regional 5-HTT BPND was demonstrated in patients 
with variety of diagnoses, including obsessive-compulsive disorder (Matsumoto 
et al., 2010), unipolar and bipolar depression (Hammoud et al., 2010; Oquendo 
et al., 2007; Parsey et al., 2006), high-functioning autism (Nakamura et al., 
2010), impulsive aggression (Frankle et al., 2005a) and methamphetamine 
abuse (Sekine et al., 2006). 5-HTT density was found unaffected or normal in 
recovered male patients with depression (Bhagwagar et al., 2007), former male 
users of MDMA ‘ecstasy’ (Selvaraj et al., 2009) and in patients, mostly males, 
with type II alcoholism (Martinez et al., 2009) or schizophrenia (Frankle et al., 
2005b). On the contrary, the recent PET study by Cannon and colleagues (2007) 
found that patients with unipolar and bipolar depression had similarly  elevated 
5-HTT density in the thalamus, insula and striatum, but showed distinct 
abnormalities in the brainstem. However, the effect of gender was not assessed 
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in this study, which included more females than males. Additionally, while no 
difference in 5-HTT BPND was detected between patients with acute unipolar 
depression and HV, the subgroup of patients with highly negativistic dys-
functional attitudes had significantly higher 5-HTT density in several brain 
regions, including prefrontal cortex, anterior cingulate, thalamus, bilateral 
caudate and bilateral putamen (Meyer et al., 2004). The effect of gender in this 
study was not reported. Conclusively, PET studies have shown that only bipolar 
and probably some subtypes of unipolar depression might be characterized by 
higher brain 5-HTT availability; however, these data lack consistence and are 
not supported for males distinctively.  
Several other aspects should be taken into account when interpreting our 
data. Although some structural MRI studies had detected a higher incidence of 
anatomical abnormalities in the brain of PD patients, particularly decreased 
volume in the temporal lobe, amygdala, parahippocampal gyrus and putamen 
(Vythilingam et al., 2000; Massana et al., 2003; Uchida et al., 2003; Yoo et al., 
2005), but increased grey matter volume in the midbrain and left insula 
(Protopopescu et al., 2006; Uchida et al., 2008) as well as greater cingulate 
white matter connectivity (Han et al., 2008), no significant regional volume 
differences were detected between PD patients and HV in the present study, 
indicating that increased 5-HTT BPND in our male patients could not be 
explained by structural changes. Importantly, control subjects underwent PET 
scans during the same seasonal intervals as PD patients to minimize possible 
seasonal effects on 5-HTT binding (Praschak-Rieder et al., 2008). Additionally 
patients and controls did not significantly differ in respect to body mass index, 
smoking and allelic or genotypic frequencies of 5-HTT-linked promoter region 
polymorphism, which also minimize possible bias. Finally, although most of the 
studied brain regions withstood FDR correction, larger samples are still required 
to replicate our findings.  
In summary, we obtained evidence of gender-dependent differences in the 
availability of brain 5-HTT in patients with PD. Male but not female PD 
patients demonstrated widespread alterations in the density of brain 5-HTT. 
These findings advance and challenge current understanding of the involvement 
of 5-HTT in panicogenesis. Other neuroimaging studies have demonstrated 
lower brain 5-HTT availability in depressed (Staley et al., 2006) and healthy 
(Jovanovic et al., 2008) females, as well as lower brain 5-HT synthesis rate 
(Nishizawa et al., 1997), but higher 5-HT1A receptor BP (Jovanovic et al., 
2008) in females than in males. However, no sex differences in brain 5-HTT 
availability were detected in a large sample of HV (Praschak-Rieder et al., 
2008). Thus, further investigations are needed to clarify the impact of gender-
distinct functions of the 5-HT system on the expressions of various mood and 
anxiety disorders, including PD. 
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Study 4. The effect of 6-week treatment with escitalopram on CCK-4 chal-
lenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.   
Pre-challenge data. The groups (Dp vs pD) did not significantly differ in their 
gender (p=0.367) or mean age (p=0.490). The distribution of 5-HTTLPR 
genotypes was similar between the groups: 42.9% in pD group and 36.4% in Dp 
group with LL genotype; 28.6% in pD and 45.5% in Dp with LS genotype; and 
28.6% in pD and 18.2% in Dp with SS genotype (p=0.846). The groups were 
also similar in all other pre-challenge variables. No significant effect of active 
treatment or placebo on any of the pre-challenge variables was observed, and no 
significant differences between the groups in any of the pre-challenge baseline 
variables (psychological or cardiovascular) were detected between different 
challenge days.  
Post-challenge effects - panic attacks. After the first treatment period, 8 of 
11 (72.7% (95% CI 39.0...94.0%)) treated with ESC and 4 of 7 (57.1% (95% CI 
18.4...90.1%)) treated with placebo had a PA during the second challenge. On 
the 3rd challenge performed after the second treatment period, 4 of 7 (57.1% 
(95% CI 18.4...90.1%)) treated with ESC and 6 of 11 (54.5% (95% CI 
23.4...83.3%)) treated with placebo experienced a PA (Figure 2).  
Pooling the data of all subjects independent of treatment, a remarkable 
reduction in panic rates was observed in the course of the first treatment period: 
from the 18 subjects who all had a PA on the 1st challenge, 12 (66.7% (95% CI 
41.0...86.7%)) had PA on the 2nd challenge and 10 (55.6% (95% CI 
30.6...78.5%)) on the 3rd challenge. The difference between the 2nd and 3rd 
challenge was not significant (χ2=0.005, df=1, p=0.943). Comparing the 
frequencies of PA in the ESC-treated subjects on the 2nd and 3rd challenge no 
significant differences were found between the challenges (p=0.742). The same 
appeared to be valid for the groups of placebo pre-treated subjects (p>0.9).  
Pooling the data of both treatment types (second and third challenge), 10 
subjects of 18 (55.6%) had a PA during challenge after treatment with placebo, 
(4 of 7 (57.1%) in the pD group and 6 of 11 (54.5%) in the Dp group). During 
the challenge after treatment with ESC, 12 of 18 subjects (66.7%) had PA (4 of 
7 (57.1%) in the pD group and 8 of 11 (72.7%) in the Dp group).  The carry-
over effect of treatment, the time effect as well as the drug effect all were not 
significant. As there was no carry-over or time effects, the proportions of PA 
were compared among drug receivers (12 of 18) and placebo receivers (10 of 
18), and the difference was not significant (χ2=0.1169, df=1, p=0.732).  
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Figure 2. Proportion of subjects responding to CCK-4 challenge with a panic attack.  
Abbreviations: PA- Panic attack, Dp – group that received ESC prior to second provo-
cation and placebo prior to third provocation; pD – group that received placebo prior to 
second and ESC prior to third provocation. 
 
 
Other variables. Also for the rest of the variables the carry-over effect, the 
time effect and the drug effect were not significant. After Holm-Bonferroni 
correction the difference of second and third provocation from the first did not 
appear significant for any of the variables assessed. 
Effect of 5-HTTLPR polymorphism. The effect of 5-HTTLPR polymorphism 
was assessed comparing SS vs. SL vs. LL as well as SS+SL vs. LL and LL+LS 
vs. SS. Neither main effect of 5-HTTLPR polymorphism nor the effect of 5-
HTTLPR polymorphism and treatment interaction were significantly associated 
with any of the outcome variables. 
Gender effect. A secondary analysis with breakdown by gender did not reveal 
any significant differences in panic rates by gender after correction for multiple 
testing. No significant gender or gender-treatment interaction effects were 
detected for any other variables after correction for multiple testing. 
 
Discussion. In the present study we observed a significant reduction in the rate 
of CCK-4-induced PA after 6-week treatment with either ESC or placebo in 
CCK-4-sensitive HV. After the first treatment period, the overall pre-treatment 
CCK-4-induced panic rate of 100% was reduced to 72.7% (8 of 11) with ESC 
and 57.1% (4 of 7) with placebo. 
These findings partly concur with studies in patients with PD, showing that 
5-HT-ergic antipanic antidepressants lessen CCK-4-induced PA (Bradwejn & 
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Koszycki, 1994b; Shlik et al., 1997; van Megen et al., 1997; Tõru et al., 2006). 
However, in contrast to the findings in patients with PD, where the drug 
outperformed placebo (van Megen et al., 1997), no significant difference in 
response to CCK-4 challenge was observed between the ESC and placebo 
conditions. The same was valid for the second treatment period. While the 
reduction in CCK-4-induced panic rate in PD patients treated with a 5-HT- 
agent has been attributed to an increased availability of synaptic 5-HT, the 
similarity between the reduction in CCK-4-induced panic rate after both ESC 
and placebo treatments in our study questions the importance of synaptic 
availability of 5-HT in CCK-4-induced panic proneness in HV.  
Similarly to our study, Kellner and colleagues (2009) found no inhibitory 
effect of ESC upon CCK-4-induced panic symptoms in HV. Plausibly, level of 
synaptic 5-HT may be affected differently in PD patients than in HV, e.g. SSRI 
may change the level of 5-HT in PD patients, but not, or much less so, in HV.  
Differences in 5-HTT and 5-HT1A receptor densities between PD patients and 
HV may explain different responses to ESC. So, Maron and colleagues (2004a) 
showed in a SPECT study that patients with current PD had significantly lower 5-
HTT binding in the midbrain raphe, in the temporal lobes and in the thalamus, 
while the patients in remission had significantly lower 5-HTT binding only in the 
thalamus. Neumeister and colleagues (2004), using PET, demonstrated a marked 
reduction of 5-HT1A receptor binding in the anterior and posterior cingulate 
cortices, and in the midbrain raphe in patients with PD compared to HV. Nash and 
colleagues (2008) have demonstrated in another PET study a reduced 5-HT1A 
receptor binding in the raphe region and in the amygdala as well as in the 
orbitofrontal and temporal cortices in untreated PD patients, with reduced density in 
the raphe and in the hippocampus persisting after recovery with an SSRI 
paroxetine. Altogether these data suggest state-, trait- and regional differences in 
brain 5-HT function between HV and patients with PD that may result in a different 
response to a 5-HT-ergic treatment.  
However SSRIs do seem to increase 5-HT synaptic levels in HV as 
demonstrated in the studies by Attenburrow and colleagues (2001), Bhagwagar 
and colleagues (2002), and Kellner and colleagues (2009), showing significant 
increases of plasma cortisol and prolactin after active treatment, indicating the 
central effects of the drug. Also Argyropoulos and colleagues (2008) have 
found major effects of most SSRIs on 5HT-sensitive sleep measures in HV.  
Notably, not all the patients receiving treatment with a 5-HT-ergic agent 
improve, e.g. according to Otto and colleagues (2001), ca 45% of PD patients 
treated with an SSRI in controlled trials failed to achieve panic-free status. This 
may further imply that increased level of synaptic 5-HT may not be sufficient 
for achieving panic-free status, at least not in all patients. Also the data of 
Schruers and Griez (2004), who found that 6-week treatment with tianeptine, an 
antidepressant that in contrast to SSRIs is believed to increase 5-HT reuptake, 
had an antipanic effect in 35% CO2 panic challenge in PD patients similarly to 
the effect seen with the SSRI paroxetine, support the notion that the hypothesis 
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of a direct causal relationship between increased level of synaptic 5-HT and 
protection from PA may be oversimplified, or at least depends on the type of 
challenge used (Bell et al., 2002). 
The CCK receptor function hypothesis for PD proposed by Bradwejn and 
Koszycki (1994b) and further outlined by Tõru and colleagues (2006) also 
deserves consideration in the present context. It suggests that SSRIs alter CCK 
neurotransmission in PD patients through desensitizing the postulated CCK-2 
receptor (CCK-2R) hypersensitivity (Bradwejn & Koszycki, 1994a). It is 
theorized that an increase in synaptic 5-HT causes an increased release of CCK 
(Raiteri et al., 1993; Rosen et al., 1995) resulting over time in a downregulation 
of CCK receptors, and thus, in a decreased sensitivity to CCK-4 challenge. 
Assuming that CCK-2R sensitivity in HV is already relatively low, the 
increased 5-HT levels are not likely to decrease CCK-2R sensitivity or cause 
only a small decrease that we could not detect. 
The reduction in panic rates on repeated challenges seen in our study warrants a 
discussion on its possible causes. While panic rates decreased with both treatments 
after the first treatment episode, active treatment did not differ from placebo and 
numerically the reduction in panic rates was even more pronounced after placebo. 
This suggests that the observed reduction resulted from the placebo effect. After the 
second treatment episode, the reduction in panic rates seen with placebo was again 
numerically, but not significantly, bigger than with ESC, implying that ESC did not 
have any specific effect. In the first of the two earlier CCK-4 challenge studies with 
SSRIs that used placebo-controlled design, Van Megen and colleagues (van Megen 
et al., 1997) found a significant decrease in panic rate after treatment with 
fluvoxamine (from 76% to 29%), but not after placebo (from 67% to 56%), 
supporting the idea of superiority of 5-HT-ergic drug over placebo. On the other 
hand, while comparing the treatment groups with respect to decline in panic rate 
from day 1 to day 56, they did not find significant group effect, suggesting that the 
difference between placebo and active treatment may have been not robust. In a 
more recent study, Kellner and his group (2009) showed no significant effect of 
treatment (ESC vs. placebo) on pre-CCK-4 challenge or CCK-4-induced increases 
in panic symptom scores in healthy males. Moreover, in the subjects with 5-
HTTLPR s/s genotype, the increase in panic scores after CCK-4 was significantly 
higher after ESC, suggesting a stronger effect of placebo. A substantial placebo 
effect on CCK-4-induced panic was also observed in several other studies assessing 
the treatment effect of non-SSRI drugs (Depot et al., 1999; Zwanzger et al., 2003; 
Kronenberg et al., 2005). Thus, the accumulating data suggest at least some role for 
placebo effect in modulating the panicogenic effects of CCK-4. 
The aspects of novelty or anticipation may also be pertinent to the 
decreasing rate of CCK-4-induced PA on repeated challenges. The novelty may 
result in anxious interpretation of the emerging symptoms that could amplify 
overall intensity of response according to the cognitive model of clinical PA 
(Wells, 1997). In some subjects, after eliminating the novelty component, the 
potential of CCK-4 to induce PA may become lower. Such habituation might fit 
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with the present data where only the subjects who responded to the initial CCK-
4 challenge with PA were selected for further study. It is plausible, that 
cognitive factors e.g. higher anticipation rather than the hypothesized higher 
sensitivity of CCK-2 receptors were crucial in determining panic reaction to the 
first challenge in some subjects. As by the second challenge the novelty had 
disappeared, the potential of CCK-4 to induce panic might have fallen below 
the critical level in some subjects explaining at least partly the reduction of 
panic rates from the 1st to 2nd challenge. Some, but not all previous studies have 
also implied a role for anticipation and habituation in response to panic 
challenges (Bradwejn et al., 1992; 1994; Aluoja et al., 1997; Zwanzger et al., 
2001; Radu et al., 2003; Eser et al., 2007; 2008; Hinkelmann et al., 2010; Tõru 
et al., 2010). Thus, anticipation or other psychological factors may be involved 
in determining the response to a laboratory challenge. 
In the present study, apart from reduction in panic rates, no significant 
effects of either treatment were detected on any other panic or anxiety-related 
characteristics after corrections for multiple testing. Also in the study of Kellner 
and colleagues (2009) no significant differences in treatment effect on any 
CCK-4-induced panic indices were observed Thus, the findings in HV are in 
contrast to the findings in patients with PD, where in addition to changes in 
panic rates, treatment induced changes in several other characteristics of panic 
response have been observed, although not consistently (Bradwejn & Koszycki, 
1994b; Shlik et al., 1997; van Megen et al., 1997). These differences may be 
explained by more robust panic responses to CCK-4 and higher sensitivity to 
antipanic treatment in the patients leading to more pronounced changes in panic 
responses as a result of treatment. On the other hand, corrections for multiple 
comparisons seemed to be omitted in the earlier studies, leaving the option open 
for overstating significance of the differences. 
 
Effect of gender 
Although PD is more frequent in females than in males (Kessler et al., 2006) 
the CCK-4-induced panic does not seem to be robustly gender-dependent. In 
our recent study with more than 100 HV we found that panic rate was similar in 
males and females (Tõru et al., 2010). Nevertheless, as gender dependent 
regional differences in brain 5-HTT binding properties (Maron et al., 2011) as 
well as in some genes involved in regulation of serotonergic activity (Maron et 
al., 2010a) have been reported, one might assume gender effects on 5-HT-CCK 
interaction patterns. However, the findings of the present study argue against a 
major role of gender in the treatment response to an SSRI or placebo.  
 
Effects of 5-HTTLPR  
Although the major influence of 5-HTTLPR in PD remains unproven (Blaya et al., 
2007; Maron et al., 2010a), there are data suggesting that 5-HTTLPR variance 
might have at least some role (Hamilton et al., 1999; Maron et al., 2005a). There 
are also some data demonstrating that 5-HTTLPR genotype may influence 
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vulnerability to experimentally induced panic (Schmidt et al., 2000). On the 
contrary, in PD patients CO2 reactivity was not influenced by 5-HTTLPR genotype 
(Perna et al., 2004). There are also preliminary data suggesting that 5-HTTLPR 
variance gender-dependently influences the treatment response to a 5-HT-ergic 
agent both in PD patients and in HV (Maron et al., 2004b; Perna et al., 2005; 
Kellner et al., 2009). Our present data did not reveal any significant effects of 5-
HTTLPR variants on treatment response. It cannot be excluded however, that our 
negative result is a consequence of insufficient sample size resulting in very small 
genotype subgroups. Also, we did not take into account the third functional variant 
of the l allele (Neumeister et al., 2006).   
Several methodological issues of the present study should be noted. First, 
there is a possibility that the drug treatment was insufficient. Although the ESC 
dose of 10 mg/day is commonly used and effective in clinical practice (Stahl et 
al., 2003), it positions on the lower end of dosages used (Townsend & Conrad, 
2007). Further, the mean ESC plasma levels in our sample (15.24 in Dp group 
and 23.9 in pD group), although comparable to mean values seen in clinical 
settings (Baumann et al., 2004; Reis et al., 2009), fell into the lower part of 
recommended therapeutic range (Baumann et al., 2004). Also, the ESC plasma 
concentrations in our sample varied remarkably between the individuals and the 
different assessments of the same individual (expanding from 1.1 ng/ml to 
41.35 ng/ml), thus concentration of ESC could have been below the effective 
level in some cases. Further, the 6-week duration of treatment may have been 
insufficient to cause changes in the 5-HT system necessary for the reduction of 
panic response to CCK-4. Finally, the possible confounding effect of the 
menstrual cycle phase on response to CCK-4 (Le Melledo et al., 1999) could 
not be taken into account in present study due to protocol demands for 
challenge times. 
In conclusion, the present study demonstrates that in CCK-4-sensitive HV 6-
week treatment with an SSRI ESC or placebo both significantly reduce the rate 
of CCK-4-induced PA. However, differently from what was found in patients 
with PD, the effect of medication was not different from placebo. Accumulating 
data suggest that the phenomena of placebo effect and habituation may have a 
bigger role in the context of pharmacological modulation of CCK-4-induced 
panic than assumed after initial studies. The exact nature of mechanisms 
underlying the reduction in CCK-4 sensitivity seen in our sample e.g. increased 
5-HT availability, placebo effect of both treatments, desensitization of 
receptors, dissipation of novelty, remains to be clarified. Our data call for 
caution in applying CCK-4 challenge in HV to screen antipanic properties of 
drugs, particularly in respect to the effects of chronic treatment, and question 
the validity of pre-selected CCK-4-sensitive HV as a proxy for patients with PD 
in this type of studies. 
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GENERAL DISCUSSION 
 
The presented studies were conducted in order to investigate the modulatory 
role of 5-HT on CCK-4-induced PA in respect to the pathophysiology of PD. 
Studies 1 and 4 focused on the direct influence of 5-HT availability on CCK-4-
induced panic response. Studies 2 and 3 investigated the relationship of panic 
propensity to biogenetic markers, such as the variations in 5-HT-ergic genes 
and the brain 5-HTT binding, which could explain the differences between HV 
and patients with PD in their susceptibility to PA and response to treatment.  
Two opposing hypotheses have been put forth to explain panic phenomena 
by 5-HT-ergic dysfunction: 5-HT excess or overactivity (Iversen, 1984; Kahn et 
al., 1988a; Kahn et al., 1988b) and 5-HT deficit or underactivity (Deakin & 
Graeff, 1991; Bell & Nutt, 1998). While the 5-HT excess theory suggests that 
patients with PD either have an increased level of 5-HT release or a hyper-
sensitivity in postsynaptic 5-HT receptors, the 5-HT deficit theory proposes 
that, in particular brain regions, such as the dorsal periaqueductal gray (PAG), 
5-HT has a restraining effect on panic behavior and a 5-HT deficit may 
facilitate panic. Although both theories are substantiated by some data, the 
accumulating evidence from clinical and experimental research preferably 
supports the inhibitory influence of 5-HT on panic (Maron & Shlik, 2005).  
A number of studies have addressed the antipanic effect of 5-HT in the 
context of experimental panic challenge with CCK-4. Several investigations in 
patients with PD have shown that the treatment with 5-HT-ergic antidepressants 
reduced CCK-4 sensitivity (Bradwejn & Koszycki, 1994b; Shlik et al., 1997; 
van Megen et al., 1997), assumingly by increasing the level of synaptic 5-HT. 
In HV, an acute pre-treatment with 5-HT precursor 5-HTP significantly reduced 
manifestations of CCK-4-induced panic, particularly in females (Maron et al., 
2004c). Our present results (Tõru et al., 2006); Tõru et al., submitted), 
concurring with some other studies (Koszycki et al., 1996; Depot et al., 1999; 
Kellner et al., 2009) challenge this straightforward hypothesis and suggest that 
the interactions between 5-HT and CCK may be more complex. Specifically, 
we found (Tõru et al., 2006) that an acute decline in the central availability of 5-
HT did not reverse the protective effect of SSRI treatment on CCK-4-induced 
panic in HV. Although a nearly 30% panic rate, similar to what was previously 
observed with CCK-4 challenge after SSRI treatment in patients with PD (Shlik 
et al., 1997; van Megen et al., 1997), suggested that the sensitivity to CCK-4 
challenge was effectively decreased by the treatment with CIT in this study, the 
lack of the effect of TD seems to contradict the notion of crucial importance of 
synaptic 5-HT level in determining the panic response to CCK-4 challenge, 
inferred from the earlier studies. Specifically, although TD by itself was not 
panicogenic in unmedicated PD patients (Goddard et al., 1994), it increased 
ventilation in PD patients (Kent et al., 1996) and revealed susceptibility to PA 
when combined with such challenge agents as adrenergic stimulant yohimbine 
(Goddard et al., 1995) or inhaled carbon dioxide (Miller et al., 2000; Schruers 
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et al., 2000). Furthermore, TD reversed the antipanic effect of treatment with an 
SSRI paroxetine in PD patients when using a challenge with flumazenil, a 
benzodiazepine receptor antagonist (Bell et al., 2002). On the other hand, 
Koszycki and colleagues (1996) demonstrated that without influencing the 
panicogenic effect of CCK-4, TD augmented CCK-4-induced release of ACTH, 
cortisol and prolactin in healthy males, suggesting that 5-HT systems may have 
a role in the neuroendocrine, but not in the psychological actions of CCK-4.  
Altogether these findings seem to support the notion that the increase in 
synaptic 5-HT conveys protection against panic. However, while some of these 
studies suggest, that the antipanic effect of SSRI-s may crucially depend upon 
the availability of 5-HT in the brain, and that the decrease in 5-HT neuro-
transmission has a potential to increase the vulnerability to PA, others indicate, 
that the effect of reduction in brain 5-HT on panic propensity is not very robust, 
and may affect only part of panic symptomatology, if at all. Furthermore, a 
study by Depot and colleagues (Depot et al., 1999) suggested that CCK-5-HT 
interactions may be complex. They reported that an acute administration of a 
selective 5-HT3-receptor antagonist ondansetron significantly decreased CCK-
4-induced panic in healthy males and reduced cortisol, growth hormone and 
prolactin response. Thus, at least in regard to 5-HT3 receptors, a reduction 
rather than increase in 5-HT effects was associated with the alleviation of CCK-
4-induced panic. Furthermore, these effects dissipated upon chronic treatment 
with ondansetron, indicating that adaptive changes that abolish the initial effect 
are likely to occur. 
In contrast to the findings in patients with PD, treatment with an antipanic 
SSRI ESC in CCK-4-sensitive HV did not cause a reduction of CCK-4-induced 
PA beyond the effect of placebo (Tõru et al., submitted). While the reduction in 
CCK-4-induced panic rate in PD patients treated with a 5-HT-ergic agent has 
been attributed to an increased availability of synaptic 5-HT, the similarity 
between the reduction in CCK-4-induced panic rate after ESC and placebo 
treatments in our study questions the importance of synaptic availability of 5-
HT in CCK-4-induced panic proneness in HV. Similarly to our study, Kellner 
and colleagues (2009) found no inhibitory effect of ESC upon CCK-4-induced 
panic symptoms in HV. Plausibly, the level of synaptic 5-HT may be affected 
differently in PD patients than in HV, e.g. SSRI may change the level of 5-HT 
in PD patients, but not, or much less so, in HV. The difference in response to 5-
HT-ergic modulation of CCK-induced panic between HV and PD patients was 
also observed in the studies with a 5-HT3 receptor antagonist ondansetron, 
which acutely attenuated CCK-4-induced PA in HV (Depot et al., 1999), but 
did not prevent the panicogenic effects of CCK-4 analogue pentagastrin in 
patients with PD (McCann et al., 1997).  
The brain imaging studies of 5-HTT and 5-HT1A have been used to test the 
5-HT functional differences between patients with PD and HV. The initial 
SPECT study by Maron and colleagues (Maron et al., 2004a) showed that when 
compared to HV, the patients with current PD had significantly lower 5-HTT 
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binding in the midbrain raphe, in the temporal lobes and in the thalamus, while 
the patients in remission had significantly lower 5-HTT binding only in the 
thalamus. Neumeister and colleagues (2004), using PET, have demonstrated a 
marked reduction of 5-HT1A receptor binding in the anterior and posterior 
cingulate cortices, and in the midbrain raphe in patients with PD compared to 
HV. Nash and colleagues (2008) have demonstrated, in another PET study, a 
reduced 5-HT1A receptor binding in the raphe region and in the amygdala, as 
well as in the orbitofrontal and temporal cortices in untreated PD patients, and 
still reduced density of 5-HT1A receptors in the raphe and in the hippocampus 
after recovery achieved with an SSRI paroxetine. Although the preliminary 
findings of reduced 5-HTT binding in PD (Maron et al., 2004a) were not 
replicated in a recent PET study (Maron et al., 2011), a higher 5-HTT binding 
potential in males with PD than in male controls was detected in the majority of 
the studied brain regions. However, no significant differences were found 
between the female PD patients and female controls. Altogether, these data 
suggest gender, state and trait dependent regional differences in the brain 5-HT 
turnover between the HV and patients with PD that may result in distinctive 
response to 5-HT-ergic treatment.  
Another line of research has addressed the genetic aspects of 5-HT system in 
HV and PD patients. In line with the findings in patients with PD (Maron et al., 
2007), we detected an association between TPH2 rs1386494 polymorphism and 
susceptibility to CCK-4-induced PA in HV (Maron et al., 2008b). This finding 
indicates possible importance of this polymorphism, respective gene, and 5-HT 
in the mechanisms of panic. However, none of the other 5-HT-related 
polymorphisms previously associated with PD (5-HTTLPR, MAO-A VNTR, 5-
HTR1A 1019CG (rs6295), 5-HTR2A 102TC (rs6313)) was linked to CCK-4-
induced PA with the exception of 5-HTR2A 102T-C, where T alleles were 
associated with a higher anxiety response to CCK-4 challenge. The TPH gene 
finding remains inconclusive, as it may not withstand a more conservative 
estimation of significance with correction for multiple comparisons. Moreover, 
the allelic distributions of this variation and associations with PD phenotype in 
patients and CCK-4-induced PA in HV were reversed, indicating the need for 
replication and explanation of such discrepancy. Notably, the findings of this 
study did not confirm our preliminary evidence of the associations between 5-
HTTLPR and panic response to CCK-4 challenge in smaller sample of HV 
(Maron et al., 2004b). Overall, the data concerning genetic factors modulating 
susceptibility to PA and PD at present stage need to be interpreted with caution, 
as most of the findings are negative or inconclusive, and only the COMT 
Val158Met (rs4680) polymorphism has been implicated in several studies and 
confirmed in a recent meta-analysis.  
Aside of possible differences in 5-HT turnover between HV and PD patients, 
the SSRIs increase 5-HT synaptic levels in HV as demonstrated in the studies 
by Attenburrow and colleagues (2001), Bhagwagar and colleagues (2002), and 
Kellner and colleagues (2009), showing significant effect on  plasma cortisol 
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and prolactin after active treatment, indicating the central effects of the drug. 
Also Argyropoulos and colleagues (2008) have found major effects of most 
SSRIs on 5HT-sensitive sleep measures in HV. Thus, the lack of antipanic 
efficacy of SSRI-s in HV seen in our study (Tõru et al., submitted) as well as in 
the study of Kellner and colleagues (2009) cannot be ascribed to the lack of 
central effects of the drug. Notably, the clinical studies show that not all PD 
patients respond to SSRIs (Otto et al., (2001), implying that increased level of 
synaptic 5-HT may not always be sufficient for achieving panic-free status. 
Also the findings of Schruers and Griez (2004) that 6-week treatment with 
tianeptine, an antidepressant that in contrast to SSRIs is believed to increase 5-
HT reuptake, had an antipanic effect in 35% CO2 panic challenge in PD patients 
similarly to the effect seen with the SSRI paroxetine, support the notion that the 
hypothesis of a direct causal relationship between increased synaptic 5-HT and 
protection from PA may be oversimplified, or at least depends on the type of 
challenge used (Bell et al., 2002). 
Altogether, the data presented so far suggest that the reduced sensitivity to 
CCK-4 after SSRI treatment may be related to mechanisms other than 5-HT 
availability in the brain. One possible explanation is that SSRIs alter CCK 
neurotransmission, perhaps through the desensitization of postulated CCK-2R 
receptor hypersensitivity (Bradwejn & Koszycki, 1994b), where variation in 
CCK-2R sensitivity may also explain the difference in panicogenic properties of 
CCK-4 between PD patients and HV (Bradwejn et al., 1991). Increasing brain 
5-HT leads to an increased release of brain CCK (Raiteri et al., 1993; Rosen et 
al., 1995) that might over time down-regulate CCK receptors. Thus, SSRIs may 
initially increase the effects of CCK, perhaps explaining the early worsening in 
anxiety seen with these drugs in some patients, but the later desensitization of 
CCK-2R occurs independently of 5-HT availability in the synaptic cleft. Such 
explanation is compatible with the preclinical data on SSRI administration 
showing an initial increase in CCK transmission and the number of CCK 
receptors (Rosen et al., 1995; Koks et al., 1999). These effects apparently 
normalize upon chronic treatment, as demonstrated by Harro and colleagues 
(1997), who found no changes in the density of CCK receptors or in the content 
of CCK-related peptides after long-term treatment with various antidepressants, 
including SSRIs. If the sensitivity of CCK-2R, and not the synaptic availability 
of 5-HT, is a critical factor determining the reactivity to a CCK-4 challenge, 
then the effects of acute TD on CCK-4 sensitivity would not be as strong as the 
effects seen with other challenge agents in both, HV (Goddard et al., 1995; 
Klaassen et al., 1998; Miller et al., 2000) and, even more robustly, PD patients 
(Kent et al., 1996; Miller et al., 2000; Schruers et al., 2000), including those in 
remission (Bell et al., 2002). This hypothesis also concurs with the findings of 
Koszycki and colleagues (1996) showing lack of a robust effect of reduced level 
of synaptic 5-HT on CCK-4-induced panic. It is also compatible with the results 
of Kellner and colleagues (2009) and our study in HV (Tõru et al, submitted). 
Namely, assuming that CCK-2R sensitivity in HV is already relatively low, the 
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SSRI-induced higher 5-HT levels are not likely to decrease CCK-2R sensitivity 
or cause only  small decrease that remained undetected. 
Another explanation of the observed reduction in CCK-4-induced panic rates 
after treatment with an SSRI is the placebo effect. In the first of the two earlier 
CCK-4 challenge studies with SSRIs that used placebo-controlled design, Van 
Megen and colleagues (1997) found a significant decrease in CCK-4-induced 
panic rate after treatment with fluvoxamine, but not after placebo. However, on 
comparison of treatment groups over the course of treatment, they did not find a 
significant group effect, suggesting that the difference between placebo and 
active treatment may have not been robust. In a more recent study, Kellner and 
colleagues (2009) showed no significant effect of treatment with ESC vs. 
placebo on pre-CCK-4 challenge or CCK-4-induced increases in panic 
symptoms in healthy males. Moreover, in the subjects with 5-HTTLPR S/S 
genotype, the increase in panic intensity after CCK-4 was significantly higher 
after ESC, suggesting a stronger effect of placebo. A substantial placebo effect 
on CCK-4-induced panic was also observed in several other studies assessing 
the treatment effect of non-SSRI drugs (Depot et al., 1999; Zwanzger et al., 
2003; Kronenberg et al., 2005). Thus, the accumulating data suggest at least 
some role for placebo effect in modulating the panicogenic effects of CCK-4. 
The aspects of novelty or anticipation may also be pertinent to the 
decreasing rate of CCK-4-induced PA on repeated challenges. The novelty may 
result in anxious interpretation of the emerging symptoms that could amplify 
overall intensity of response according to the cognitive model of clinical PA 
(Wells, 1997). In some subjects, after eliminating the novelty component, the 
potential of CCK-4 to induce PA may become lower. Such habituation might fit 
with the data of our study (Tõru et al., submitted), where only the subjects who 
responded to the initial CCK-4 challenge with PA were included. It is plausible 
that cognitive factors, e.g. higher anticipation, were crucial in determining panic 
reaction to the first challenge in some subjects. As by the second challenge the 
novelty was lacking, the potential of CCK-4 to induce panic might have fallen 
below the critical level explaining the reduction of panic rates from the 1st to 2nd 
challenge. Some (pro refs), but not all (con refs) previous studies have also 
implied a role for anticipation and habituation in response to panic challenges 
(Bradwejn et al., 1992; Bradwejn et al., 1994; Aluoja et al., 1997; Zwanzger et 
al., 2001; Radu et al., 2003; Eser et al., 2007; Eser et al., 2008; Hinkelmann et 
al., 2010; Tõru et al., 2010). Thus, anticipation or related psychological factors 
may be involved in determining the response to a laboratory challenge.  
To conclude, it would apparently be an oversimplification to consider 5-HT 
system as the single or primary modulatory factor in determining the CCK-4-
induced panic response as well as to assume a direct modulatory effect of 5-HT 
on CCK-4 induced panic. The molecular and receptor mechanisms behind the 
5-HT effects on panic manifestations observed in the context of CCK-4 
challenge warrant further studies. The specific effects of different subsets of 5-
HT system and their respective regulating mechanisms, e.g. receptor subtypes, 
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regional differences in receptor binding properties and gene effects, require 
clarification. Importantly, both CCK and 5-HT systems affect and are 
influenced by many other neurotransmitters in the brain circuitry involved in 
processing and expression of panic and anxiety (Coplan & Lydiard, 1998). To 
capture an integrated view on panic mechanisms, the complex character of the 
5-HT system itself as well as the interaction patterns between different 
neurotransmitter systems and psychological modulators have to be taken into 
account. A better understanding of 5-HT - CCK interaction patterns and 
underlying mechanisms should lead toward more comprehensive view on the 
mechanisms of PA and contribute to the improved clinical management of PD.   
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CONCLUSIONS 
 
1.  Acute decline in the central availability of 5-HT by means of TD did not 
reverse the protective effect of SSRI treatment on CCK-4-induced panic. 
This outcome differs from the findings with another panicogen, flumazenil, 
suggesting a distinctive modulatory role of 5-HT in response to various 
challenge agents. 
 
2.   On a panel of candidate genes, only rs1386494 A/G polymorphism in TPH2 
gene was associated with CCK-4-induced panic attacks in HV with the 
frequencies of G/G genotype and G allele significantly higher in panickers. 
Other polymorphisms previously associated with PD were unrelated to 
CCK-4-induced PA, probably due to the differences between complex nature 
of PD and laboratory panic model. 
 
3.  5-HTT BPND was significantly higher in 13 of 20 studied brain regions, 
including several cortical and raphe areas, but lower in the hippocampus in 
males with PD as compared with healthy males. No significant differences in 
5-HTT BPND were observed between female patients and controls. These 
results suggest gender-dependent regional differences in the brain 5-HTT 
availability and converge with previous PET findings of reduced 5-HT1A 
receptor binding in similar brain areas in PD. Distinctive functioning of the 
5-HT system in males and females may underlie certain gender differences 
in expressions of PD. 
 
4.  The treatment with SSRI ESC did not reduce the CCK-4-induced PA in 
CCK-4-sensitive HV beyond the effect of placebo in contrast to the findings 
in patients with PD. These results suggest that placebo effect and habituation 
may have a bigger role in the context of pharmacological modulation of 
CCK-4-induced panic than assumed previously. The exact nature of the 
mechanisms underlying the reduction in CCK-4 sensitivity (e.g. increased 5-
HT availability, placebo effect of both treatments, desensitization of 
receptors, dissipation of novelty) remains to be clarified. Our data call for 
caution in applying CCK-4 challenge in HV to screen antipanic properties of 
drugs, particularly in respect to the effects of chronic treatment, and question 
the validity of pre-selected CCK-4-sensitive HV as a proxy for patients with 
PD in this type of studies. 
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SUMMARY IN ESTONIAN 
 
CCK-4 poolt indutseeritud  
paanikavastuse serotonergiline modulatsioon 
 
Sissejuhatus 
Paanikahäire, üks põhilistest ärevushäiretest, on sage (esinemissagedus aasta 
jooksul 2.8% ning elu jooksul 4.7%) ning tõsine probleem nii seda põdevale 
haigele kui ühiskonnale (Kessler et al., 2006). Paanikahäiret iseloomustavad 
korduvad ootamatud paanikahood ning hirm nende taastekkimise või nendest 
tingitud võimalike kahjulike tagajärgede ees, mis sageli viib agorafoobia lisan-
dumiseni (DSM-IV, RHK-10) (WHO, 1992; APA, 1994). Paanikahäire ja 
paanikahoogude uurimisel on edukalt rakendatud erinevaid eksperimentaalseid 
mudeleid, teiste hulgas paanikahoogude esilekutsumist koletsüstokiniini tetra-
peptiidi CCK-4-ga (Eser et al., 2007; Kellner, 2012). CCK-4 on endogeense 
neuropeptiidi sünteetiline analoog, mis, sõltuvalt annusest, tingib paanika-
häirega haigetel spontaanselt esinevate paanikahoogudega sarnaste paanika-
hoogude tekke nii paanikahäirega haigetel kui tervetel vabatahtlikel, kusjuures 
viimased on vähem tundlikud (Bradwejn et al., 1991). 
Paanikafenomeni paremaks mõistmiseks on uuritud ka CCK ning teiste 
neurotransmitterite interaktsioone. Mitmed uuringud on keskendunud seroto-
niini ning selle eelkäija trüptofaani moduleerivale mõjule CCK-4-poolt esile 
kutsutud sümptomitele nii paanikahäirega haigetel (Bradwejn & Koszycki, 
1994b; Shlik et al., 1997; van Megen et al., 1997) kui tervetel vabatahtlikel 
(Koszycki et al., 1996; Depot et al., 1999; Maron et al., 2004c). Nimetatud 
uuringud on näidanud, et tõhus paanikavastane ravi serotonergilise ravimiga, 
mis eeldatavasti tõstab sünaptilise 5-HT taset, vähendab paanikahäirega haigetel 
CCK-4 poolt indutseeritud paanikahoogude hulka ning intensiivsust. Tervete 
vabatahtlike puhul on tulemused 5-HT ning trüptofaani moduleeriva mõju kohta 
CCK-4 poolt indutseeritud  paanikasümptomitele olnud vastuolulisemad.  
Varasemad uuringud osutasid erinevustele nii paanikahäirega haigete ning 
tervete vabatahtlike tundlikkuses CCK-4-mõjule kui ka selle tundlikkuse 
serotonergilises moduleerimises. Leitud erinevused tundusid olevat, vähemalt 
osaliselt, seletatavad erinevustega paanikahäirega haigete ning tervete vabataht-
like aju serotonergilistes retseptor- ning transportersüsteemides (Maron et al., 
2004a; Neumeister et al., 2004; Nash et al., 2008) ning serotoniinisüsteemi tööd 
reguleerivate geenide aktiivsuses (Hamilton et al., 1999; Maron et al., 2004b; 
Maron et al., 2005a; Perna et al., 2005).  
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Uurimistöö põhieesmärgid 
Käesoleva uurmistöö peaeesmärgiks oli täiendavalt hinnata serotoniinisüsteemi 
moduleerivat rolli CCK-4 poolt indutseeritud paanikavastusele paanikahäirega 
haigetel ja tervetel vabatahtlikel. Lisaks aju serotoniintaseme otsese farmako-
loogilise manipuleerimise mõjule uuriti ka mõnede hüpoteetiliselt oluliste 
taustafaktorite (mõnede serotonergiliste geenide variatsioonide ning aju seroto-
niini transporteri süsteemi) rolli. 
Töösse kaasatud uuringute spetsiifilised eesmärgid olid järgmised: 
1.  Uurida trüptofaani akuutse depletsiooni mõju CCK-4 poolt tingitud 
paanikasümptomitele paanikahäirega haigetel, kes olid eelnevalt positiivselt 
reageerinud ravile SSTI tsitalopraamiga.  
2.  Hinnata üheksa varasemalt paanikahäirega seostatud kandidaatgeeni variat-
sioonide (5-HTTLPR, MAO-A VNTR, TPH2 rs1386494, 5-HTR1A 
−1019C–G, 5-HTR2A 102T–C, CCKR1 246G–A, CCKR2 −215C–A, 
DRD1 −94G–A and COMT Val158Met) seoseid CCK-4 poolt tervetel vaba-
tahtlikel esile kutsutud paanikavastusega. 
3.  Hinnata võrdlevalt serotoniini transporteri sidumisvõimet (a non-displace-
able brain 5-HTT binding potential (BPND)) aju erinevates piirkondades 
paanikahäirega mees- ja naishaigetel ning soo ja vanuse mõttes sobitatud 
tervetel vabatahtlikel kasutades positronemissioon-tomograafiat ning radio-
aktiivset markerit [11C]MADAM.  
4.  Hinnata SSTI estsitalopraami 6-nädalase ravikuuri mõju CCK-4 poolt indut-
seeritud paanikasümptomitele CCK-4-le „tundlikel“ tervetel vabatahtlikel 
(olid eelnevalt reageerinud CCK-4 manustamisele paanikahooga).  
 
 
Uuringute metoodika 
Kõik uuringud teostati Tartu Ülikooli Psühhiaatriakliinikus, PET ja MRT uurin-
gud teostati Turu Ülikooli PET Keskuses. Kõigi uuringute protokollid olid 
heaks kiidetud vastavate institutsioonide eetikakomiteede poolt, kõik uuritavad 
allkirjastasid informeeritud nõusoleku vormi. 
Esimene uuring hindas trüptofaani depletsiooni (TD) poolt tingitud aju 
serotoniinitaseme ajutise languse mõju CCK-4 poolt tingitud paanikavastusele 
paanikahäirega haigetel, kes olid eelnevalt reageerinud 10 nädalasele ravile 
SSTI tsitalopraamiga. Uuringu eksperimentaalsesse faasi kaasati 18 paanika-
häirega haiget (6 meest, 12 naist,  keskmine vanus 34.5±9.3), kelle seisund 
uuringu alguses oli vastanud käesoleva paanikahäire diagnostilistele tunnustele, 
kellel 10.-nädalaks ei olnud tsitalopraamikuuri (keskmine annus 18.9±4.4 mg/p; 
vahemik 10–30 mg/p) mõjul esinenud vähemalt 2 eelnenud nädala vältel 
paanikahoogu ning kelle seisund oli raviarsti hinnangul ravi käigus palju või 
väga palju paranenud; eksperimentaalse perioodi kestel ravi jätkus. TD/CCK-4 
provokatsioonid teostati topeltpimedal, platseebokontrollitud, tasakaalustatud 
ristuvate gruppide meetodil, mille kohaselt iga haige osales ca nädalase vahega 
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kahel sarnase korraldusega provokatsioonil. Depletsioonipäeval said haiged 
provokatsioonile eelnevalt trüptofaanivaba ning platseebopäeval trüptofaani 
sisaldava aminohappeid sisaldava joogi. Jookide järjekord määrati juhuslikult, 
joogid segati, järgides standardset protokolli (Young et al., 1985). 5 tundi pärast 
aminohapete manustamist võeti vereanalüüs trüptofaani sisalduse määramiseks 
ning teostati CCK-4 provokatsioon – veenisisese süstena manustati ca 3 sekundi 
jooksul 25 µg füsioloogilises lahuses lahustatud CCK-4. Vastavalt protokollile 
hinnati CCK-4 mõju mitmetele käitumuslikele ning kardiovaskulaarsetele 
parameetritele.  
Teine uuring hindas võimalikke seoseid 9 varasemalt paanikahäirega seos-
tatud geenipolümorfismi (5-HTTLPR, MAO-A VNTR, TPH2 rs1386494, 5-
HTR1A −1019C–G, 5-HTR2A 102T–C, CCKR1 246G–A, CCKR2 −215C–A, 
DRD1 −94G–A and COMT Val158Met) ning  CCK-4 poolt tervetel vabataht-
likel esile kutsutud paanikavastuse vahel. Uuringus osales 110 ajalehekuulutuse 
peale pöördunud tervet vabatahtlikku (47 meest, 63 naist, keskmine vanus 
22.2±5.2). Kaasamiseks pidi uuritav olema vanuses 18–50 aastat, nõutav oli 
psüühikahäirete puudumine käesolevalt ning ka anamneesis (seda nii uuritaval 
kui lähisugulastel), hea kehaline tervis ning eelneva CCK-4 provokatsiooni-
kogemuse puudumine. Uuringupäeval manustati uuritavatele eelnevalt paigal-
datud veenikanüüli kaudu kiire süstena füsioloogilises lahuses lahustatud CCK-
4 (50 µg). Süste eelselt ning järgselt mõõdeti regulaarselt protokollis määratud 
käitumuslikke ning kardiovaskulaarseid karakteristikuid. Genotüpiseerimiseks 
võeti vereanalüüs, millest DNA eraldati kasutades standardset fenool-kloroform 
ekstraktsioonimeetodit. Polümorfismide määramine toimus vastavalt varem 
kirjeldatud protokollidele (Lesch et al., 1996; Sabol et al., 1998; Maron et al., 
2007). Hinnati võimalike seoste olemasolu määratud geenivariatsioonide ning 
CCK-4 poolt indutseeritud paanikahoogude, aga ka muude mõõdetud provokat-
sioonivastuse karakteristikute vahel. 
Kolmas uuring hindas võrdlevalt serotoniin transporteri sidumisvõimet (a 
non-displaceable brain 5-HTT binding potential (BPND)) aju erinevates piir-
kondades paanikahäirega mees- ja naishaigetel ning soo ja vanuse mõttes 
sobitatud tervetel vabatahtlikel kasutades positron- emissioontomograafiat ning 
radioaktiivset markerit [11C]MADAM. Uuringus osales 11 ravita (vähemalt 4 
kuud) paanikahäirega haiget (5 meest, 6 naist; keskmine vanus 31.1±8.6) ning 
24 tervet vabatahtlikku (12 meest, 12 naist; keskmine vanus 36.9±6.9). Kõik 
uuritavad olid kehaliselt terved. Haiged värvati SA TÜK Psühhiaatriakliiniku 
haigete hulgast, terved vabatahtlikud (nõutav oli psüühikahäirete puudumine 
anamneesis nii uuritaval kui lähisugulastel) kuulutuse vahendusel (Tartust ning 
Turust). [11C]MADAM valmistati vastavalt varem avaldatud protokollile 
(Halldin et al., 2005). PET uuringud toimusid Turu Ülikooli PET keskuses 
kasutades kõrge lahutusvõimega spetsiaalset PET kaamerat HRRT (Siemens 
Medical Solutions, Knoxville, TN). PET uuring ning järgnev kujutiste analüüs 
toimus varemkirjeldatud protokolli kohaselt (Hirvonen et al., 2008).  
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Neljas uuring hindas 6-nädalase estsitalopraami kuuri mõju CCK-4 provo-
katsioonivastusele eelnevalt CCK-4 mõjul paanikahoo saanud tervetel vaba-
tahtlikel. Uuring koosnes 2-st osast. 82 uuritavat (29 meest, 53 naist; keskmine 
vanus 22.3±5.0), osales uuringu esimeses osas (manustati 50µg CCK-4). 37 
(45.1%) uuritavale, kellel avaldus provokatsiooni käigus paanikahoog, tehti 
ettepanek osaleda uuringu teises osas, 27 neist nõustus. Uuringu teine osa 
koosnes topeltpimeda disainiga 6-nädalasest raviperioodist estsitalopraami (10 
mg/p) või platseeboga, sellele järgnenud nädalasest väljauhtumisperioodist ning 
järgmisest 6 nädalasest raviperioodist ümbervahetatud ravimiga. Kummagi ravi-
faasi lõpus leidis aset CCK-4 provokatsioon (50µg CCK-4). Uuringu ravifaasis 
langes 4 vabatahtlikku välja (3 kõrvaltoimete, 1 raseduse tõttu). 4 uuritavat 
lülitati edasisest analüüsist välja puuduliku ravisoostumuse ning üks uuritav 
statistilis-metodoloogiliste kaalutluste tõttu, lõppanalüüsi lülitati 18 uuritava (10 
meest, 8 naist, keskmine vanus 22.5±5.8) andmed. Plasma estsitalopraami 
kontsentratsiooni määramiseks võeti vereanalüüs kummagi raviperioodi kahes 
ajapunktis, kontsentratsiooni määramiseks kasutati vedelikkromatograafilist – 
massspektromeetrilist süsteemi (Agilent Series 1290 Infinity LC, Santa-Clara, 
CA, USA), uuritavate genotüpiseerimine toimus vastavalt varemkirjeldatud 
protokollile (Maron et al., 2004b).  
 
 
Peamised tulemused 
Esimene uuring. TD tingis kogu- ning vaba trüptofaani keskmise taseme lan-
guse vastavalt 73 ning 69%; pärast kontrolljooki tõusid vaba- ja kogutrüptofaani 
keskmised tasemed vastavalt 369 and 138%; keskmine TRP/LNAA suhe langes 
TD päeval 92% ning kontrollpäeval 46%. CCK-4 põhjustas mõlemal provo-
katsioonipäeval paanikahoo võrdselt ca 1/3-l haigetest (TD n=5, 27.8%, kontroll  
n=6, 33.3%; χ2=0.13, df=1, p=0.72); ka ühegi teise hinnatud näitaja osas 
depletsioonipäeva ning kontrollpäeva vahel erinevusi ei avaldunud. 
Teine uuring. CCK-4 provokatsiooni käigus koges 110-st uuritavast 
paanikahoogu 39 (35.5%). Pärast genotüpiseerimist lülitati edasisest analüüsist 
välja kaks CCK retseptorite geenipolümorfismi – CCK2R −215C–A ning 
CCK1R 246G–A, kuna uuritavate hulgas ei esinenud kummagi SNP A alleeli 
kandjat. 5- HTTLPR genotüüpide ning alleelisageduste osas gruppide vahel 
olulisi erinevusi ei olnud. Võrreldes S alleeli kandjatega oli LL genotüübiga 
uuritavatel vahetult enne CCK provokatsiooni oluliselt kõrgem baasärevuse tase 
(VAS-iga mõõdetud) (p = 0.02). Ükski muu hinnatud ärevuse parameeter 5-
HTTLPR polümorfismiga ei seostunud. MAO-A VNTR polümorfism ei korre-
leerunud paanikahoogude ega ühegi muu hinnatud ärevuse parameetriga.  TPH2 
geeni rs1386494 A/G polümorfismi osas esines gruppide vahel oluline erine-
vus – nimelt esines paanikahoo saanud uuritavatel G/G genotüüpi ning G alleeli 
oluliselt enam. Edasine analüüs näitas gruppidevahelist olulist erinevust naiste 
(vastavalt p=0.038 ning p=0.048), mitte aga meeste osas (vastavalt p=0.26 ning 
p=0.09). Ühegi muu  mõõdetud parameetriga nimetatud polümorfism oluliselt 
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seotud ei olnud. Ülejäänud uuritavatest polümorfismidest ükski CCK-4 poolt 
indutseeritud paanikavastusega ei seostunud. Täiendav analüüs näitas, et 5-
HT1A −1018 polümorfismi CC genotüübiga uuritavatel  oli kõrgem skoor PSS 
kognitiivsete sümptomite alaskaalal kui CG või GG genotüübi kandjatel 
(F(2.11)=3.5; p=0.03) ning  et 5-HT2A 102 polümorfismi TT genotüübi kand-
jatel tingis CCK-4 kõrgema ärevuse tõusu VAS skaalal kui CT või CC  geno-
tüübi kandjatel (F(2.11)=3.1; p=0.049).  
Kolmas uuring. Analüüs näitas olulist interaktsiooni grupi ning uuritavate 
soo vahel (F=15.93, p<0.001) ning ka grupi, uuritavate soo ja ajupiirkonna 
vahel (F=5.51, p=0.015), mis osutas gruppide soost sõltuvatele regionaalsetele 
erinevustele serotoniini transporteri sidumisvõimes (5-HTT BPND). Erinevused 
avaldusid mitmes paanikahäire patofüsioloogia seisukohalt olulises ajupiir-
konnas, nimelt dorsaalses eesmises tsingulaarkoores (F=12.20, p=0.002), me-
diaalses (F=6.59, p=0.016) ja dorsolateraalses (F=10.18, p=0.003) prefrontaal-
koores, insula eesmises (F=7.26, p=0.011) ja tagumises (F=10.35, p=0.003) 
osas, mediaalses (F=13.39, p=0.001) ja lateraalses (F=7.54, p=0.010) orbito-
frontaalkoores, keskmises (F=7.75, p=0.009) ja ülemises (F=5.89, p=0.021) 
temporaalkäärus, angulaarkäärus (F=10.44, p=0.003), hipokampuses (F=4.34, 
p=0.046) ning raphe tuumades (F=7.11, p=0.012). Edasine analüüs näitas, et 
PH-ga meestel oli 5-HTT BPND kõnealustes piirkondades võrrledes tervete 
kontrollisikutega oluliselt kõrgem, välja arvatud hipokampuses, kus 5-HTT 
BPND oli oluliselt madalam. Naiste puhul gruppide (PH vs TV) vahel olulist 
erinevust ei avaldunud. Kogu grupi nagu ka naissoost uuritavate osas 5-HTT 
BPND ning enne PET uuringut täidetud kliiniliste skaalade skooride vahel olulist 
seost ei avaldunud. Meeshaigetel korreleerusid 5-HTT BPND väärtused HAS 
skooridega positiivselt dorsaalses eesmises tsingulaarkoores (R=0.90, p=0.038), 
dorsaalses sabatuumas (R=0.94, p=0.020), eesmises insulaarkäärus (R=0.98, 
p=0.003), mediaalses frontaalkoores (R=0.94, p=0.019) ning lateraalses 
(R=0.98, p=0.003) ja mediaalses orbitofrontaalkoores (R=0.93, p=0.024) ning 
PDSS skooridega ventraalses eesmises tsingulaarkoores (R=0.96, p=0.010), 
dorsaalses sabatuumas (R=0.94, p=0.019) ning lateraalses orbitofrontaalkoores 
(R=0.91, p=0.031); negatiivne korrelatsioon avaldus hipokampuses (R= – 0.97, 
p=0.006).  
Neljas uuring. Grupid (Dp (ravim-platseebo) vs pD (platseebo-ravim)) ei 
erinenud üksteisest ei soolise jaotuse, uuritavate keskmise vanuse, 5-HTTLPR 
genotüüpide jaotuse, ega ühegi muu hinnatud provokatsioonieelse karakteristiku  
(ei psühholoogilise ega kardivaskulaarse) poolest ühelgi provokatsioonipäeval. 
Kumbki, ei estsitalopraam ega platseebo, avaldanud olulist mõju ühelegi 
hinnatud provokatsioonieelsetest karakteristikutest.  
Peale esimest  ravikuuri, II provokatsioonil, sai paanikahoo 11 estsitalopraa-
miga ravitud uuritavast 8 (72.7% (95% CI 39.0...94.0%)) ning 7-st platseeboga 
ravitud uuritavast 4 (57.1% (95% CI 18.4...90.1%)). III provokatsioonil sai 7-st 
estsitalopraamiga ravitud uuritavast paanikahoo 4 (57.1% (95% CI 18.4... 
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90.1%)) ning 11-st platseeboga ravitud uuritavast 6 (54.5% (95% CI 23.4... 
83.3%)).  
Summeerides kõigi uuritavate andmed (sõltumata ravist), avaldus esimese 
ravikuuri tulemusena oluline paanikahoogude sageduse langus: 18 uuritavast, 
kes kõik olid saanud paanikahoo I provokatsioonil, said II provokatsioonil 
paanikahoo 12 (66.7% (95% CI 41.0...86.7%)) ning III provokatsioonil 10 
(55.6% (95% CI 30.6...78.5%)). II ja III provoktasiooni erinevus oli statistiliselt 
ebaoluline (χ2=0.005, df=1, p=0.943). Nii ravimõju edasikandumise, provo-
katsiooni järjekorra, kui ka ravimi efekt olid statistiliselt ebaolulised. Paanika-
hoogude esinemissagedus ravimisaajate (12 uuritavat 18-st) ning platseebo-
saajate (10 uuritavat 18-st) vahel oluliselt ei erinenud  (χ2=0.1169, df=1, p= 
0.732). Ka ühegi muu hinnatud parameetri osas gruppide vahel erinevusi ei 
olnud.  
5-HTTLPR polümorfism (võrreldes genotüüpe SS vs. SL vs. LL aga ka 
SS+SL vs. LL ning  LL+LS vs. SS), ega ka nimetatud polümorfismi ning ravi 
interaktsioon oluliselt ühegagi hinnatud parameetritest ei seostunud. Samuti ei 
olnud ühelegi hinnatud parameetrile olulist mõju uuritavate sool ega ka soo ning 
ravi interaktsioonil. 
 
 
Järeldused 
1. Trüptofaani depletsioonist tingitud aju serotoniinitaseme ajutine alandamine 
ei kaota SSTI raviga paranenud paaanikahäirega haigetel CCK-4 provokat-
sioonil avalduvat tsitalopraami paanikavastast toimet. Saadud tulemus erineb 
teist tüüpi panikogeeni – flumaseniiliga saadud tulemustest, osutades võimalike-
le erinevustele 5-HT süsteemi moduleerivas rollis erinevate panikogeenide 
korral.  
2. Trüptofaani hüdroksülaasi 2 isovormi polümorfism 1386494A/G seostus 
positiivselt CCK-4 poolt tingitud paanikahoogudega tervetel vabatahtlikel, 
kusjuures G/G genotüübi ja G alleeli esinemissagedus oli oluliselt kõrgem 
uuritavatel, kes said provokatsiooni käigus paanikahoo. Käesolev tulemus, toe-
tades varasemat paanikahäirega haigetel läbiviidud uuringus saadud   tulemust, 
osutab TPH2 rs1386494 polümorfismi ning paanikavalmiduse vahelisele 
võimalikule seosele. Ükski teine uuritud kandidaatgeenide variatsioonidest 
tervetel vabatahtlikel CCK-4 poolt indutseeritud paanikahoogudega ei assot-
sieerunud, osutades muuhulgas ilmselt teatud erinevustele kompleksse loomu-
sega paanikahäire ning laboratoorse paanikamudeli vahel. 
3. Serotoniin transporteri sidumisvõime (5-HTT BPND) oli paanikahäirega 
meestel võrreldes tervete meestega oluliselt kõrgem 13-s uuritud 20-st ajupiir-
konnast, sealhulgas mitmes kortikaalses ning raphe piirkonnas; madalam aga 
hipokampuse piirkonnas. Naiste puhul tervete ning paanikahäirega haigete 
vahel aju serotoniin transporteri (5-HTT BPND) sidumisvõime osas piirkond-
likke erinevusi ei avaldunud. Saadud tulemused osutavad uuritavate soost 
sõltuvatele regionaalsetele erinevustele serotoniini transporteri tiheduses.  
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Leitud funktsionaalsed erinevused 5-HT süsteemis  meeste ja naiste vahel 
võivad osaliselt seletada mõningaid soolisi erinevusi paanikahäire avaldumises. 
4. Erinevalt paanikahäirega haigetest, ei alandanud ravi SSTI–ga CCK-4-le 
tundlike tervete vabatahtlike puhul paanikahoogude sagedust enam kui plat-
seebo. Meie tulemused osutavad, et CCK-4 toime farmakoloogilise modulat-
siooni kontekstis võib platseebo- ja/või habituatsiooniefektil olla esialgselt 
oletatust olulisem tähendus. Käesolevas uuringus täheldatud CCK-4–tundlik-
kuse languse täpsed põhjused (aju 5-HT taseme tõus, retseptorite desensitisat-
sioon, platseeboefekt, uudsuse kadu) vajavad selgitamist edasistes uuringutes. 
Saadud tulemused süvendavad kahtlusi, mis on tekkinud CCK-4 provokatsiooni 
rakendatavuse osas uute paanikavastaste ravimite katsetamiseks tervetel vaba-
tahtlikel ning muudavad küsitavaks eelnevalt selekteeritud CCK-4 suhtes 
tundlike tervete vabatahtlike kasutamise otstarbekuse sedalaadi uuringutes. 
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